



Clinical trial results:

A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant- Adapted BNT162b2 RNA-Based Vaccine Candidate (s) in Healthy Children

Summary

EudraCT number	2024-000001-33
Trial protocol	Outside EU/EEA
Global end of trial date	

Results information

Result version number	v3 (current)
This version publication date	11 May 2025
First version publication date	06 March 2024
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	C4591048
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05543616
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	BioNTech SE
Sponsor organisation address	An der Goldgrube 12, Mainz, Germany, 55131
Public contact	BioNTech SE, BioNTech clinical trials patient information, +49 6131 90840, patients@biontech.de
Scientific contact	BioNTech SE, BioNTech clinical trials patient information, +49 6131 90840, patients@biontech.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-002861-PIP02-20
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	31 October 2024
Is this the analysis of the primary completion data?	No

Global end of trial reached?	No
------------------------------	----

Notes:

General information about the trial

Main objective of the trial:

Substudy (SS) B: Assess safety, tolerability of bivalent BNT162b2 as 3rd/4th doses in participants ≥ 6 months to < 5 years. Compare anti-Omicron BA.4/BA.5 immune response in those receiving 3 prior 3 mcg doses of BNT162b2 vs. 4th dose in Group 2, and Phase 2/3 Study C4591007 participants with 3 doses of 3 mcg BNT162b2. SSC: Assess safety, tolerability of bivalent BNT162b2 as 4th dose in participants 6M- < 5 Y. Evaluate immune responses to 4th dose in this group. SSD: Assess safety, tolerability of bivalent BNT162b2 as 3rd/4th doses in 5-12Y. Compare anti-Omicron BA.4/BA.5 immune response in 5-12Y receiving 3 doses of 10 mcg BNT162b2 vs. 4th dose in Group 2, and Study C4591007 participants with 3 doses of 10 mcg. SSE: Evaluate safety, tolerability of prophylactic BNT162b2 (Omicron XBB.1.5) as a single dose in COVID-19 vaccine-naïve participants ≥ 5 - < 12 years, and immune response compared to vaccine-experienced participants ≥ 12 years of age of BNT162b2 (Omi XBB.1.5) in Study C4591054 SSA.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 September 2022
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 1843
Country: Number of subjects enrolled	Brazil: 29
Country: Number of subjects enrolled	Puerto Rico: 2
Country: Number of subjects enrolled	South Africa: 65
Worldwide total number of subjects	1939
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	145

months)	
Children (2-11 years)	1794
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Substudy (SS)B:1398 participants enrolled, 1397 vaccinated. SSC:100 randomised, 98 vaccinated.SSD:136 enrolled,134 vaccinated. SSE:310 enrolled and vaccinated. Data was reported at study completion date for SSB, SSC, SSD & SSE. PCD for SSA have not been reached; data collection is still ongoing, hence no data reported for SSA.

Period 1

Period 1 title	Baseline Period
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	SSB: Group 1a: 2 prior doses of BNT162b2
------------------	--

Arm description:

Participants aged ≥ 6 months to < 2 years who had received two prior doses of BNT162b2 3 microgram (mcg) with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 1b: 2 prior doses of BNT162b2
------------------	--

Arm description:

Participants aged ≥ 2 to < 5 years who had received two prior doses of BNT162b2 3 mcg with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 2a: 3 prior doses of BNT162b2
------------------	--

Arm description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 2b: 3 prior doses of BNT162b2
------------------	--

Arm description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 3a: 3 prior doses of BNT162b2
------------------	--

Arm description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 3b: 3 prior doses of BNT162b2
------------------	--

Arm description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSC: Group 1a: 3 prior doses of BNT162b2
------------------	--

Arm description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants

received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
6 micrograms Bivalent BNT162b2 administered intramuscularly.	
Arm title	SSC: Group 1b: 3 prior doses of BNT162b2

Arm description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
10 micrograms Bivalent BNT162b2 administered intramuscularly.	
Arm title	SSC: Group 2a: 3 prior doses of BNT162b2

Arm description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
6 micrograms Bivalent BNT162b2 administered intramuscularly.	
Arm title	SSC: Group 2b: 3 prior doses of BNT162b2

Arm description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details:	
10 micrograms Bivalent BNT162b2 administered intramuscularly.	
Arm title	SSD: Group 1: 2 prior doses of BNT162b2

Arm description:

Participants aged 5 to 11 years who had received two prior doses of BNT162b2 10 microgram (mcg) 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

10 micrograms (original BNT162b2 5 mcg and BNT162b2 Omicron [B.1.1.529 sublineage BA.4/BA.5] 5 mcg) administered intramuscularly.

Arm title	SSD: Group 2: 3 prior doses of BNT162b2
------------------	---

Arm description:

Participants aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

10 micrograms (original BNT162b2 5 mcg and BNT162b2 Omicron [B.1.1.529 sublineage BA.4/BA.5] 5 mcg) administered intramuscularly.

Arm title	SSD Group 3: Participants from study C4591007 Phase 1
------------------	---

Arm description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg at least 90 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

10 micrograms (original BNT162b2 5 mcg and BNT162b2 Omicron [B.1.1.529 sublineage BA.4/BA.5] 5 mcg) administered intramuscularly.

Arm title	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg
------------------	---

Arm description:

Participants aged 5 to 11 years who received a single dose of BNT162b2 (Omi XBB.1.5) 10 mcg via intramuscular route on Day 1 of this sub-study.

Arm type	Experimental
Investigational medicinal product name	Monovalent BNT162b2 (Omi XBB.1.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

10 micrograms BNT162b2 (Omicron XBB.1.5) administered intramuscularly.

Number of subjects in period 1	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2	SSB: Group 2a: 3 prior doses of BNT162b2
Started	17	13	92
Completed	17	13	92

Number of subjects in period 1	SSB: Group 2b: 3 prior doses of BNT162b2	SSB: Group 3a: 3 prior doses of BNT162b2	SSB: Group 3b: 3 prior doses of BNT162b2
Started	218	68	989
Completed	218	68	989

Number of subjects in period 1	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2
Started	17	19	32
Completed	17	19	32

Number of subjects in period 1	SSC: Group 2b: 3 prior doses of BNT162b2	SSD: Group 1: 2 prior doses of BNT162b2	SSD: Group 2: 3 prior doses of BNT162b2
Started	30	2	113
Completed	30	2	113

Number of subjects in period 1	SSD Group 3: Participants from study C4591007 Phase 1	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg
Started	19	310
Completed	19	310

Period 2

Period 2 title	Phase 1
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Blinding implementation details:

Single blinded sponsor open label

Arms

Are arms mutually exclusive?	No
------------------------------	----

Arm title	SSC: Group 1a: 3 prior doses of BNT162b2
Arm description: Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.	
Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details: 6 micrograms BNT162b2 administered intramuscularly.	
Arm title	SSC: Group 1b: 3 prior doses of BNT162b2
Arm description: Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.	
Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details: 10 micrograms BNT162b2 administered intramuscularly.	
Arm title	SSC: Group 2a: 3 prior doses of BNT162b2
Arm description: Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.	
Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details: 6 micrograms BNT162b2 administered intramuscularly.	
Arm title	SSC: Group 2b: 3 prior doses of BNT162b2
Arm description: Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.	
Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use
Dosage and administration details: 10 micrograms BNT162b2 administered intramuscularly.	

Number of subjects in period 2	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2
Started	17	19	32
Completed	17	18	32
Not completed	0	1	0
Lost to follow-up	-	1	-

Number of subjects in period 2	SSC: Group 2b: 3 prior doses of BNT162b2
Started	30
Completed	30
Not completed	0
Lost to follow-up	-

Period 3

Period 3 title	Phase 3
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded
Blinding implementation details:	
Open Label Period	

Arms

Are arms mutually exclusive?	Yes
Arm title	SSB: Group 1a: 2 prior doses of BNT162b2

Arm description:

Participants aged ≥ 6 months to < 2 years who had received two prior doses of BNT162b2 3 microgram (mcg) with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 1b: 2 prior doses of BNT162b2
-----------	--

Arm description:

Participants aged ≥ 2 to < 5 years who had received two prior doses of BNT162b2 3 mcg with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was

administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 2a: 3 prior doses of BNT162b2
------------------	--

Arm description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 2b: 3 prior doses of BNT162b2
------------------	--

Arm description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 3a: 3 prior doses of BNT162b2
------------------	--

Arm description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSB: Group 3b: 3 prior doses of BNT162b2
------------------	--

Arm description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 2 to < 5 years who had received

three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 micrograms Bivalent BNT162b2 administered intramuscularly.

Arm title	SSD: Group 1: 2 prior doses of BNT162b2
------------------	---

Arm description:

Participants aged 5 to 11 years who had received two prior doses of BNT162b2 10 microgram (mcg) 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

10 micrograms (original BNT162b2 5 mcg and BNT162b2 Omicron [B.1.1.529 sublineage BA.4/BA.5] 5 mcg) administered intramuscularly.

Arm title	SSD: Group 2: 3 prior doses of BNT162b2
------------------	---

Arm description:

Participants aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

10 micrograms (original BNT162b2 5 mcg and BNT162b2 Omicron [B.1.1.529 sublineage BA.4/BA.5] 5 mcg) administered intramuscularly.

Arm title	SSD Group 3: Participants from study C4591007 Phase 1
------------------	---

Arm description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg at least 90 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Arm type	Experimental
Investigational medicinal product name	Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

10 micrograms (original BNT162b2 5 mcg and BNT162b2 Omicron [B.1.1.529 sublineage BA.4/BA.5] 5 mcg) administered intramuscularly.

Arm title	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg
------------------	---

Arm description:

Participants aged 5 to 11 years who received a single dose of BNT162b2 (Omi XBB.1.5) 10 mcg via intramuscular route on Day 1 of this sub-study.

Arm type	Experimental
Investigational medicinal product name	Monovalent BNT162b2 (Omi XBB.1.5)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

10 micrograms BNT162b2 (Omicron XBB.1.5) administered intramuscularly.

Number of subjects in period 3	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2	SSB: Group 2a: 3 prior doses of BNT162b2
Started	17	13	92
Completed	17	11	89
Not completed	0	2	3
Physician decision	-	-	-
Consent withdrawn by subject	-	-	-
Withdrawal by parents/guardian	-	2	3
Lost to follow-up	-	-	-
Protocol deviation	-	-	-

Number of subjects in period 3	SSB: Group 2b: 3 prior doses of BNT162b2	SSB: Group 3a: 3 prior doses of BNT162b2	SSB: Group 3b: 3 prior doses of BNT162b2
Started	218	68	989
Completed	210	67	969
Not completed	8	1	20
Physician decision	-	-	1
Consent withdrawn by subject	-	-	-
Withdrawal by parents/guardian	7	-	4
Lost to follow-up	-	1	12
Protocol deviation	1	-	3

Number of subjects in period 3	SSD: Group 1: 2 prior doses of BNT162b2	SSD: Group 2: 3 prior doses of BNT162b2	SSD Group 3: Participants from study C4591007 Phase 1
Started	2	113	19
Completed	2	111	19
Not completed	0	2	0
Physician decision	-	-	-
Consent withdrawn by subject	-	1	-
Withdrawal by parents/guardian	-	1	-
Lost to follow-up	-	-	-

Protocol deviation	-	-	-
--------------------	---	---	---

Number of subjects in period 3	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg
Started	310
Completed	287
Not completed	23
Physician decision	-
Consent withdrawn by subject	-
Withdrawal by parents/guardian	1
Lost to follow-up	17
Protocol deviation	5

Baseline characteristics

Reporting groups

Reporting group title	SSB: Group 1a: 2 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received two prior doses of BNT162b2 3 microgram (mcg) with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.

Reporting group title	SSB: Group 1b: 2 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received two prior doses of BNT162b2 3 mcg with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.

Reporting group title	SSB: Group 2a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 2b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 3a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 3b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 1a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 1b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 2a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 2b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a

single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSD: Group 1: 2 prior doses of BNT162b2
-----------------------	---

Reporting group description:

Participants aged 5 to 11 years who had received two prior doses of BNT162b2 10 microgram (mcg) 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSD: Group 2: 3 prior doses of BNT162b2
-----------------------	---

Reporting group description:

Participants aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSD Group 3: Participants from study C4591007 Phase 1
-----------------------	---

Reporting group description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg at least 90 days before enrollment in the study were included.

Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg
-----------------------	---

Reporting group description:

Participants aged 5 to 11 years who received a single dose of BNT162b2 (Omi XBB.1.5) 10 mcg via intramuscular route on Day 1 of this sub-study.

Reporting group values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2	SSB: Group 2a: 3 prior doses of BNT162b2
Number of subjects	17	13	92
Age categorical			
Units: Subjects			
In Utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days - 23 months)	17	0	92
Children (2 - 11 years)	0	13	0
12 - 17 years	0	0	0
Adults (18 - 64 years)	0	0	0
From 65 - 84 years	0	0	0
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Male	12	6	51
Female	5	7	41
Race			
Units: Subjects			
White	14	7	64
Black or African American	0	0	2
Asian	1	4	11
Multiracial	1	2	15
Not reported	1	0	0
Native Hawaiian or other Pacific Islander	0	0	0
American Indian or Alaska Native	0	0	0
Ethnicity			
Units: Subjects			

Hispanic/Latino	3	2	18
Non-Hispanic/non-Latino	13	11	74
Not reported	1	0	0

Reporting group values	SSB: Group 2b: 3 prior doses of BNT162b2	SSB: Group 3a: 3 prior doses of BNT162b2	SSB: Group 3b: 3 prior doses of BNT162b2
Number of subjects	218	68	989
Age categorical Units: Subjects			
In Utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days - 23 months)	0	68	0
Children (2 - 11 years)	218	0	989
12 - 17 years	0	0	0
Adults (18 - 64 years)	0	0	0
From 65 - 84 years	0	0	0
85 years and over	0	0	0
Gender categorical Units: Subjects			
Male	105	38	477
Female	113	30	512
Race Units: Subjects			
White	153	58	775
Black or African American	7	5	51
Asian	18	3	57
Multiracial	39	2	100
Not reported	1	0	2
Native Hawaiian or other Pacific Islander	0	0	1
American Indian or Alaska Native	0		3
Ethnicity Units: Subjects			
Hispanic/Latino	34	12	136
Non-Hispanic/non-Latino	184	56	852
Not reported	0	0	1

Reporting group values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2
Number of subjects	17	19	32
Age categorical Units: Subjects			
In Utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days - 23 months)	17	0	32
Children (2 - 11 years)	0	19	0
12 - 17 years	0	0	0

Adults (18 - 64 years)	0	0	0
From 65 - 84 years	0	0	0
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Male	9	8	16
Female	8	11	16
Race			
Units: Subjects			
White	13	18	25
Black or African American	0	1	2
Asian	2	0	2
Multiracial	2	0	3
Not reported	0	0	0
Native Hawaiian or other Pacific Islander	0	0	0
American Indian or Alaska Native	0	0	0
Ethnicity			
Units: Subjects			
Hispanic/Latino	2	2	1
Non-Hispanic/non-Latino	15	17	31
Not reported	0	0	0

Reporting group values	SSC: Group 2b: 3 prior doses of BNT162b2	SSD: Group 1: 2 prior doses of BNT162b2	SSD: Group 2: 3 prior doses of BNT162b2
Number of subjects	30	2	113
Age categorical			
Units: Subjects			
In Utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days - 23 months)	0	0	0
Children (2 - 11 years)	30	2	113
12 - 17 years	0	0	0
Adults (18 - 64 years)	0	0	0
From 65 - 84 years	0	0	0
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Male	17	2	57
Female	13	0	56
Race			
Units: Subjects			
White	23	2	66
Black or African American	1	0	9
Asian	3	0	13
Multiracial	3	0	22
Not reported	0	0	3
Native Hawaiian or other Pacific Islander	0	0	0

American Indian or Alaska Native	0	0	0
Ethnicity			
Units: Subjects			
Hispanic/Latino	0	0	23
Non-Hispanic/non-Latino	30	2	90
Not reported	0	0	0

Reporting group values	SSD Group 3:Participants from study C4591007 Phase 1	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg	Total
Number of subjects	19	310	1939
Age categorical			
Units: Subjects			
In Utero	0	0	0
Preterm newborn infants (gestional age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days - 23 months)	0	0	226
Children (2 - 11 years)	19	310	1713
12 - 17 years	0	0	0
Adults (18 - 64 years)	0	0	0
From 65 - 84 years	0	0	0
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Male	8	146	952
Female	11	164	987
Race			
Units: Subjects			
White	12	128	1358
Black or African American	2	164	244
Asian	2	6	122
Multiracial	3	10	202
Not reported	0	1	8
Native Hawaiian or other Pacific Islander	0	0	1
American Indian or Alaska Native	0	1	4
Ethnicity			
Units: Subjects			
Hispanic/Latino	0	162	395
Non-Hispanic/non-Latino	19	148	1542
Not reported	0	0	2

Subject analysis sets

Subject analysis set title	SSB Historical cohort:C4591007 BNT162b2 >=6 months to<2 years
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants aged >=6 months to <2 years from study C4591007 (NCT04816643) who received 3 doses of original BNT162b2 3 mcg were included.	
Subject analysis set title	SSB Historical cohort: C4591007 BNT162b2 3 mcg

Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants aged ≥ 2 to < 5 years from study C4591007 (NCT04816643) who received 3 doses of original BNT162b2 3 mcg were included.	
Subject analysis set title	SSD Historical cohort: C4591007 BNT162b2 10 mcg
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants aged ≥ 5 to < 12 years from study C4591007 (NCT04816643) who received 3 doses of original BNT162b2 10 mcg were included.	
Subject analysis set title	SSE Historical Cohort: C4591054 BNT162b2 (Omi XBB.1.5) 30mcg
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants aged ≥ 12 years who had received single dose of BNT162b2 (Omi XBB.1.5) 30 mcg in study C4591054 [NCT05997290]. Only the relevant data was used for analysis as planned, these participants were not enrolled in this study.	

Reporting group values	SSB Historical cohort: C4591007 BNT162b2 ≥ 6 months to < 2 years	SSB Historical cohort: C4591007 BNT162b2 3 mcg	SSD Historical cohort: C4591007 BNT162b2 10 mcg
Number of subjects	72	167	113
Age categorical Units: Subjects			
In Utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days - 23 months) Children (2 - 11 years) 12 - 17 years Adults (18 - 64 years) From 65 - 84 years 85 years and over			
Gender categorical Units: Subjects			
Male Female			
Race Units: Subjects			
White Black or African American Asian Multiracial Not reported Native Hawaiian or other Pacific Islander American Indian or Alaska Native			
Ethnicity Units: Subjects			
Hispanic/Latino Non-Hispanic/non-Latino Not reported			

Reporting group values	SSE Historical Cohort: C4591054 BNT162b2 (Omi XBB.1.5) 30mcg		
Number of subjects	300		
Age categorical Units: Subjects			
In Utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days - 23 months)	0		
Children (2 - 11 years)	0		
12 - 17 years	0		
Adults (18 - 64 years)	0		
From 65 - 84 years	0		
85 years and over	0		
Gender categorical Units: Subjects			
Male	0		
Female	0		
Race Units: Subjects			
White	0		
Black or African American	0		
Asian	0		
Multiracial	0		
Not reported	0		
Native Hawaiian or other Pacific Islander	0		
American Indian or Alaska Native	0		
Ethnicity Units: Subjects			
Hispanic/Latino	0		
Non-Hispanic/non-Latino	0		
Not reported	0		

End points

End points reporting groups

Reporting group title	SSB: Group 1a: 2 prior doses of BNT162b2
Reporting group description: Participants aged ≥ 6 months to < 2 years who had received two prior doses of BNT162b2 3 microgram (mcg) with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.	
Reporting group title	SSB: Group 1b: 2 prior doses of BNT162b2
Reporting group description: Participants aged ≥ 2 to < 5 years who had received two prior doses of BNT162b2 3 mcg with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.	
Reporting group title	SSB: Group 2a: 3 prior doses of BNT162b2
Reporting group description: Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSB: Group 2b: 3 prior doses of BNT162b2
Reporting group description: Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSB: Group 3a: 3 prior doses of BNT162b2
Reporting group description: Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSB: Group 3b: 3 prior doses of BNT162b2
Reporting group description: Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSC: Group 1a: 3 prior doses of BNT162b2
Reporting group description: Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSC: Group 1b: 3 prior doses of BNT162b2
Reporting group description: Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSC: Group 2a: 3 prior doses of BNT162b2
Reporting group description: Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSC: Group 2b: 3 prior doses of BNT162b2
Reporting group description: Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a	

single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSD: Group 1: 2 prior doses of BNT162b2
-----------------------	---

Reporting group description:

Participants aged 5 to 11 years who had received two prior doses of BNT162b2 10 microgram (mcg) 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSD: Group 2: 3 prior doses of BNT162b2
-----------------------	---

Reporting group description:

Participants aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSD Group 3: Participants from study C4591007 Phase 1
-----------------------	---

Reporting group description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg at least 90 days before enrollment in the study were included.

Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg
-----------------------	---

Reporting group description:

Participants aged 5 to 11 years who received a single dose of BNT162b2 (Omi XBB.1.5) 10 mcg via intramuscular route on Day 1 of this sub-study.

Reporting group title	SSC: Group 1a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 1b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 2a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 2b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 1a: 2 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received two prior doses of BNT162b2 3 microgram (mcg) with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.

Reporting group title	SSB: Group 1b: 2 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received two prior doses of BNT162b2 3 mcg with the last dose received 60 to 150 days before enrollment in the study were included. Participants received two doses (third and fourth dose) of BNT162b2 3 mcg via intramuscular route in this study. Third dose was administered on Day 1 of this study and fourth dose was administered approximately 2 months after third dose.

Reporting group title	SSB: Group 2a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 2b: 3 prior doses of BNT162b2
Reporting group description:	
Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSB: Group 3a: 3 prior doses of BNT162b2
Reporting group description:	
Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSB: Group 3b: 3 prior doses of BNT162b2
Reporting group description:	
Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSD: Group 1: 2 prior doses of BNT162b2
Reporting group description:	
Participants aged 5 to 11 years who had received two prior doses of BNT162b2 10 microgram (mcg) 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSD: Group 2: 3 prior doses of BNT162b2
Reporting group description:	
Participants aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSD Group 3: Participants from study C4591007 Phase 1
Reporting group description:	
Participants from C4591007 (NCT04816643) phase 1 trial, aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg at least 90 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.	
Reporting group title	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg
Reporting group description:	
Participants aged 5 to 11 years who received a single dose of BNT162b2 (Omi XBB.1.5) 10 mcg via intramuscular route on Day 1 of this sub-study.	
Subject analysis set title	SSB Historical cohort: C4591007 BNT162b2 ≥ 6 months to < 2 years
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants aged ≥ 6 months to < 2 years from study C4591007 (NCT04816643) who received 3 doses of original BNT162b2 3 mcg were included.	
Subject analysis set title	SSB Historical cohort: C4591007 BNT162b2 3 mcg
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants aged ≥ 2 to < 5 years from study C4591007 (NCT04816643) who received 3 doses of original BNT162b2 3 mcg were included.	
Subject analysis set title	SSD Historical cohort: C4591007 BNT162b2 10 mcg
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants aged ≥ 5 to < 12 years from study C4591007 (NCT04816643) who received 3 doses of original BNT162b2 10 mcg were included.	
Subject analysis set title	SSE Historical Cohort: C4591054 BNT162b2 (Omi XBB.1.5) 30mcg
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants aged ≥ 12 years who had received single dose of BNT162b2 (Omi XBB.1.5) 30 mcg in study C4591054 [NCT05997290]. Only the relevant data was used for analysis as planned, these	

Primary: SSB: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination 1 in Participants Aged ≥ 6 months to < 2 Years

End point title	SSB: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination 1 in Participants Aged ≥ 6 months to < 2 Years ^{[1][2]}
-----------------	--

End point description:

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after study vaccination 1. Redness and swelling were measured and recorded in mdu where, 1 mdu = 0.5 cm and were graded as mild (≥ 0.5 to 2.0 cm), moderate (> 2.0 to 7.0 cm), severe (> 7.0 cm) & Grade (G) 4 (necrosis [redness and swelling] or exfoliative dermatitis [redness]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) & G4 ER visit or hospitalisation. G4 were classified by investigator or medically qualified person. Percentage of participants with local reactions within 7 days after study vaccination 1 and associated 2-sided 95% CI based on Clopper and Pearson method. Safety population = all participants receiving at least 1 dose of study intervention. Here, n = participants evaluable for the specified rows.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination 1 (i.e. third dose for Group 1a and fourth dose for Groups 2a and 3a) Description

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 3a: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	92	68	
Units: Percentage of participants				
number (confidence interval 95%)				
Redness: Any (n=17, 92, 68)	5.9 (0.1 to 28.7)	7.6 (3.1 to 15.1)	5.9 (1.6 to 14.4)	
Redness: Mild (n=17, 92, 68)	5.9 (0.1 to 28.7)	7.6 (3.1 to 15.1)	4.4 (0.9 to 12.4)	
Redness: Moderate (n=17, 92, 68)	0 (0.0 to 19.5)	0 (0.0 to 3.9)	1.5 (0.0 to 7.9)	
Redness: Severe (n=17, 92, 68)	0 (0.0 to 19.5)	0 (0.0 to 3.9)	0 (0.0 to 5.3)	
Redness: Grade 4 (n=17, 92, 68)	0 (0.0 to 19.5)	0 (0.0 to 3.9)	0 (0.0 to 5.3)	
Swelling: Any (n=17, 92, 68)	0 (0.0 to 19.5)	5.4 (1.8 to 12.2)	1.5 (0.0 to 7.9)	
Swelling: Mild (n=17, 92, 68)	0 (0.0 to 19.5)	5.4 (1.8 to 12.2)	1.5 (0.0 to 7.9)	
Swelling: Moderate (n=17, 92, 68)	0 (0.0 to 19.5)	0 (0.0 to 3.9)	0 (0.0 to 5.3)	
Swelling: Severe (n=17, 92, 68)	0 (0.0 to 19.5)	0 (0.0 to 3.9)	0 (0.0 to 5.3)	
Swelling: Grade 4 (n=17, 92, 68)	0 (0.0 to 19.5)	0 (0.0 to 3.9)	0 (0.0 to 5.3)	
Tenderness at injection site: Any (n=17, 90, 64)	23.5 (6.8 to 49.9)	12.2 (6.3 to 20.8)	12.5 (5.6 to 23.2)	
Tenderness at injection site: Mild (n=17, 90, 64)	17.6 (3.8 to 43.4)	12.2 (6.3 to 20.8)	12.5 (5.6 to 23.2)	
Tenderness at injection site: Moderate (n=17, 90, 64)	5.9 (0.1 to 28.7)	0 (0.0 to 4.0)	0 (0.0 to 5.6)	

Tenderness at injection site:Severe (n=17,90, 64)	0 (0.0 to 19.5)	0 (0.0 to 4.0)	0 (0.0 to 5.6)	
Tenderness at injection site:Grade 4 (n=17,90,64)	0 (0.0 to 19.5)	0 (0.0 to 4.0)	0 (0.0 to 5.6)	

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination 2 in Participants Aged >=6 months to <2 Years: Group 1a Only

End point title	SSB: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination 2 in Participants Aged >=6 months to <2 Years: Group 1a Only ^{[3][4]}
-----------------	---

End point description:

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after study vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (>=0.5 to 2.0 cm), moderate (>2.0 to 7.0 cm), severe(>7.0 cm)& G4 (necrosis [redness and swelling] or exfoliative dermatitis [redness]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying),severe(causes limitation of limb movement) & G4 ER visit or hospitalisation.G4 were classified by investigator or medically qualified person. Percentage of participants with local reactions within 7 days after study vaccination 2 and associated 2-sided 95% CI based on Clopper and Pearson method. Safety population=all participants who received at least 1 dose of study intervention. This endpoint is reported for Group 1a only as only participants from Group 1a received two vaccinations in the study.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination 2 (i.e. fourth dose)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: Percentage of participants				
number (confidence interval 95%)				
Redness: Any	11.8 (1.5 to 36.4)			
Redness: Mild	11.8 (1.5 to 36.4)			
Redness: Moderate	0 (0.0 to 19.5)			
Redness: Severe	0 (0.0 to 19.5)			
Redness: Grade 4	0 (0.0 to 19.5)			
Swelling: Any	5.9 (0.1 to 28.7)			
Swelling: Mild	5.9 (0.1 to 28.7)			
Swelling: Moderate	0 (0.0 to 19.5)			

Swelling: Severe	0 (0.0 to 19.5)			
Swelling: Grade 4	0 (0.0 to 19.5)			
Tenderness at the injection site: Any	17.6 (3.8 to 43.4)			
Tenderness at the injection site: Mild	11.8 (1.5 to 36.4)			
Tenderness at the injection site: Moderate	0 (0.0 to 19.5)			
Tenderness at the injection site: Severe	5.9 (0.1 to 28.7)			
Tenderness at the injection site: Grade 4	0 (0.0 to 19.5)			

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination 1 in Participants Aged ≥ 6 months to < 2 Years

End point title	SSB: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination 1 in Participants Aged ≥ 6 months to < 2 Years ^{[5][6]}
-----------------	--

End point description:

Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after study vaccination 1. Fever: oral temperature ≥ 38.0 deg C categorised as ≥ 38.0 to 38.4 deg C, > 38.4 to 38.9 deg C, > 38.9 to 40.0 deg C and > 40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (Inconsolable; crying cannot be comforted). G4 for all events: ER visit/hospitalisation and classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population was used. n=number of participants evaluable for the specified rows.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination 1 (i.e. third dose for Group 1a and fourth dose for Groups 2a and 3a)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 3a: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	92	68	
Units: Percentage of participants				
number (confidence interval 95%)				
Fever: Any (n=17, 92, 68)	0 (0.0 to 19.5)	8.7 (3.8 to 16.4)	11.8 (5.2 to 21.9)	
Fever: ≥ 38.0 to 38.4 deg C (n=17, 92, 68)	0 (0.0 to 19.5)	6.5 (2.4 to 13.7)	2.9 (0.4 to 10.2)	

Fever: >38.4 to 38.9 deg C (n=17, 92, 68)	0 (0.0 to 19.5)	1.1 (0.0 to 5.9)	2.9 (0.4 to 10.2)	
Fever: >38.9 to 40.0 deg C (n=17, 92, 68)	0 (0.0 to 19.5)	1.1 (0.0 to 5.9)	4.4 (0.9 to 12.4)	
Fever: >40.0 deg C (n=17, 92, 68)	0 (0.0 to 19.5)	0 (0.0 to 3.9)	0 (0.0 to 5.3)	
Fever: Unknown (n=17, 92, 68)	0 (0.0 to 19.5)	0 (0.0 to 3.9)	1.5 (0.0 to 7.9)	
Decreased appetite: Any (n=17, 89, 64)	23.5 (6.8 to 49.9)	20.2 (12.4 to 30.1)	20.3 (11.3 to 32.2)	
Decreased appetite: Mild (n=17, 89, 64)	11.8 (1.5 to 36.4)	9.0 (4.0 to 16.9)	14.1 (6.6 to 25.0)	
Decreased appetite: Moderate (n=17, 89, 64)	11.8 (1.5 to 36.4)	11.2 (5.5 to 19.7)	6.3 (1.7 to 15.2)	
Decreased appetite: Severe (n=17, 89, 64)	0 (0.0 to 19.5)	0 (0.0 to 4.1)	0 (0.0 to 5.6)	
Decreased appetite: Grade 4 (n=17, 89, 64)	0 (0.0 to 19.5)	0 (0.0 to 4.1)	0 (0.0 to 5.6)	
Drowsiness: Any (n=17, 89, 64)	41.2 (18.4 to 67.1)	20.2 (12.4 to 30.1)	17.2 (8.9 to 28.7)	
Drowsiness: Mild (n=17, 89, 64)	35.3 (1 to 61.7)	18.0 (10.6 to 27.5)	15.6 (7.8 to 26.9)	
Drowsiness: Moderate (n=17, 89, 64)	5.9 (0.1 to 28.7)	2.2 (0.3 to 7.9)	1.6 (0.0 to 8.4)	
Drowsiness: Severe (n=17, 89, 64)	0 (0.0 to 19.5)	0 (0.0 to 4.1)	0 (0.0 to 5.6)	
Drowsiness: Grade 4 (n=17, 89, 64)	0 (0.0 to 19.5)	0 (0.0 to 4.1)	0 (0.0 to 5.6)	
Irritability: Any (n=17, 89, 64)	64.7 (38.3 to 85.8)	36.0 (26.1 to 46.8)	45.3 (32.8 to 58.3)	
Irritability: Mild (n=17, 89, 64)	35.3 (14.2 to 61.7)	16.9 (9.8 to 26.3)	23.4 (13.8 to 35.7)	
Irritability: Moderate (n=17, 89, 64)	23.5 (6.8 to 49.9)	18.0 (10.6 to 27.5)	21.9 (12.5 to 34.0)	
Irritability: Severe (n=17, 89, 64)	5.9 (0.1 to 28.7)	1.1 (0.0 to 6.1)	0 (0.0 to 5.6)	
Irritability: Grade 4 (n=17, 89, 64)	0 (0.0 to 19.5)	0 (0.0 to 4.1)	0 (0.0 to 5.6)	

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination 2 in Participants Aged >=6 months to <2 Years: Group 1a Only

End point title	SSB: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination 2 in Participants Aged >=6 months to <2 Years: Group 1a Only ^{[7][8]}
-----------------	---

End point description:

Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after Dose 1. Fever: oral temperature ≥ 38.0 deg C; categorised as ≥ 38.0 to 38.4 deg C, >38.4 to 38.9 deg C, >38.9 to 40.0 deg C and >40.0 deg C. Decreased appetite:mild(decreased interest in eating),moderate(decreased oral intake),severe(refusal to feed).Drowsiness: mild(increased or prolonged sleeping bouts),moderate (slightly subdued interfering with daily activity),severe(disabling;not intereste d in usual daily activity).Irritability:mild (easily consolable), moderate(requiring increased attention),severe(disabling;not interested in usual daily activity).G4 for all events:ER visit/hospitalisation and were classified by investigator or medically qualifi ed person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination 2 (i.e. fourth dose)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: Percentage of participants				
number (confidence interval 95%)				
Fever: Any	11.8 (1.5 to 36.4)			
Fever: ≥ 38.0 to 38.4 deg C	0 (0.0 to 19.5)			
Fever: >38.4 to 38.9 deg C	0 (0.0 to 19.5)			
Fever: >38.9 to 40.0 deg C	11.8 (1.5 to 36.4)			
Fever: >40.0 deg C	0 (0.0 to 19.5)			
Decreased appetite: Any	17.6 (3.8 to 43.4)			
Decreased appetite: Mild	17.6 (3.8 to 43.4)			
Decreased appetite: Moderate	0 (0.0 to 19.5)			
Decreased appetite: Severe	0 (0.0 to 19.5)			
Decreased appetite: Grade 4	0 (0.0 to 19.5)			
Drowsiness: Any	11.8 (1.5 to 36.4)			
Drowsiness: Mild	11.8 (1.5 to 36.4)			
Drowsiness: Moderate	0 (0.0 to 19.5)			
Drowsiness: Severe	0 (0.0 to 19.5)			
Drowsiness: Grade 4	0 (0.0 to 19.5)			
Irritability: Any	52.9 (27.8 to 77.0)			
Irritability: Mild	23.5 (6.8 to 49.9)			
Irritability: Moderate	23.5 (6.8 to 49.9)			
Irritability: Severe	5.9 (0.1 to 28.7)			
Irritability: Grade 4	0 (0.0 to 19.5)			

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants Reporting Adverse Events (AEs) From the First Study Vaccination to 1 Month After Study Vaccination 1 in Participants Aged ≥ 6 Months to <2 Years

End point title	SSB: Percentage of Participants Reporting Adverse Events
-----------------	--

End point description:

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this endpoint. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination on Day 1 up to 1 month after study vaccination 1 (i.e. third dose for Group 1a and fourth dose for Group 2a and 3a)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 3a: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	92	68	
Units: Percentage of participants				
number (not applicable)	5.9	10.9	14.7	

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) From the Study Vaccination to 6 Months After Last Study Vaccination in Participants Aged ≥ 6 Months to < 2 Years

End point title	SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) From the Study Vaccination to 6 Months After Last Study Vaccination in Participants Aged ≥ 6 Months to < 2 Years ^[10]
-----------------	---

End point description:

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation. Safety population included all participants who received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination up to 6 months after last study vaccination

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 3a: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	92	68	
Units: Percentage of participants				
number (not applicable)	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants Reporting Adverse Events (AEs) From the Second Study Vaccination to 1 Month After Study Vaccination 2 in Participants Aged ≥ 6 Months to < 2 Years: Group 1a Only

End point title	SSB: Percentage of Participants Reporting Adverse Events (AEs) From the Second Study Vaccination to 1 Month After Study Vaccination 2 in Participants Aged ≥ 6 Months to < 2 Years: Group 1a Only ^[11]
-----------------	--

End point description:

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination 2 were reported in this endpoint. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination 2 up to 1 month after study vaccination 2 (i.e. fourth dose)

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2			
Subject group type	Reporting group			
Number of subjects analysed	17			
Units: Percentage of participants				
number (not applicable)	5.9			

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination 2 in Participants Aged ≥ 2 to < 5 Years: Group 1b Only

End point title	SSB: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination 2 in Participants Aged ≥ 2 to < 5
-----------------	---

End point description:

Local reactions recorded by participants/parents/legal guardians in e-diary. Redness & swelling recorded in mdu converted to cm. 1 mdu=0.5 cm & graded mild: (>0.5 to 2.0 cm), moderate: >2.0 to 7.0 cm, severe: >7.0 cm, G4: necrosis/exfoliative dermatitis (redness) & necrosis (swelling). Pain at injection site graded mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity & G4: ER visit/hospitalisation. G4 classified by investigator/medically qualified person. Percentage of participants with local reactions within 7 days after study vaccination and associated 2-sided 95% CI based on Clopper and Pearson method. Safety population = all participants receiving at least 1 dose of study intervention. Number of participants analyzed = participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination 2 (i.e. third dose for Group 1b)

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1b: 2 prior doses of BNT162b2			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Percentage of participants				
number (confidence interval 95%)				
Redness: Any	0 (0.0 to 28.5)			
Redness: Mild	0 (0.0 to 28.5)			
Redness: Moderate	0 (0.0 to 28.5)			
Redness: Severe	0 (0.0 to 28.5)			
Redness: Grade 4	0 (0.0 to 28.5)			
Swelling: Any	0 (0.0 to 28.5)			
Swelling: Mild	0 (0.0 to 28.5)			
Swelling: Moderate	0 (0.0 to 28.5)			
Swelling: Severe	0 (0.0 to 28.5)			
Swelling: Grade 4	0 (0.0 to 28.5)			
Pain at the injection site: Any	9.1 (0.2 to 41.3)			
Pain at the injection site: Mild	9.1 (0.2 to 41.3)			
Pain at the injection site: Moderate	0 (0.0 to 28.5)			
Pain at the injection site: Severe	0 (0.0 to 28.5)			
Pain at the injection site: Grade 4	0 (0.0 to 28.5)			

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants With Local Reactions Within 7 Days After

Study Vaccination 1 in Participants Aged >=2 to <5 Years

End point title	SSB: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination 1 in Participants Aged >=2 to <5 Years ^{[14][15]}
-----------------	---

End point description:

Local reactions recorded by participants/parents/legal guardians in e-diary. Redness & swelling recorded in mdu converted to cm. 1 mdu=0.5 cm & graded mild: (>0.5 to 2.0 cm), moderate: >2.0 to 7.0 cm, severe: >7.0 cm, G4: necrosis/exfoliative dermatitis (redness) & necrosis (swelling). Pain at injection site graded mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity & G4: ER visit/hospitalisation. G4 classified by investigator/medically qualified person. Percentage of participants with local reactions within 7 days after study vaccination and associated 2-sided 95% CI based on Clopper and Pearson method. Safety population = all participants receiving at least 1 dose of study intervention. Number of participants analyzed = participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination 1 (i.e. third dose for Group 1b and fourth dose for Groups 2b and 3b)

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1b: 2 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB: Group 3b: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	218	986	
Units: Percentage of participants				
number (confidence interval 95%)				
Redness: Any	7.7 (0.2 to 36.0)	6.4 (3.6 to 10.5)	10.1 (8.3 to 12.2)	
Redness: Mild	0 (0.0 to 24.7)	5.5 (2.9 to 9.4)	8.8 (7.1 to 10.8)	
Redness: Moderate	7.7 (0.2 to 36.0)	0.9 (0.1 to 3.3)	1.3 (0.7 to 2.2)	
Redness: Severe	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)	
Redness: Grade 4	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)	
Swelling: Any	7.7 (0.2 to 36.0)	4.1 (1.9 to 7.7)	4.0 (2.8 to 5.4)	
Swelling: Mild	7.7 (0.2 to 36.0)	3.7 (1.6 to 7.1)	3.4 (2.4 to 4.8)	
Swelling: Moderate	0 (0.0 to 24.7)	0.5 (0.0 to 2.5)	0.5 (0.2 to 1.2)	
Swelling: Severe	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)	
Swelling: Grade 4	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)	
Pain at the injection site: Any	30.8 (9.1 to 61.4)	30.3 (24.3 to 36.8)	30.3 (27.5 to 33.3)	
Pain at the injection site: Mild	30.8 (9.1 to 61.4)	28.4 (22.6 to 34.9)	27.9 (25.1 to 30.8)	
Pain at the injection site: Moderate	0 (0.0 to 24.7)	1.8 (0.5 to 4.6)	2.5 (1.6 to 3.6)	
Pain at the injection site: Severe	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)	
Pain at the injection site: Grade 4	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)	

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination 1 in Participants Aged ≥ 2 to < 5 Years

End point title	SSB: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination 1 in Participants Aged ≥ 2 to < 5 Years ^{[16][17]}
-----------------	---

End point description:

Systemic events recorded by participants/parents/legal guardians in e-diary. Fever: oral temperature ≥ 38.0 deg C and categorised as ≥ 38.0 - 38.4 deg C, > 38.4 - 38.9 deg C, > 38.9 - 40.0 deg C & > 40.0 deg C. Fatigue, headache, chills, new/worsened muscle pain & new/worsened joint pain: mild: did not interfere with activity, moderate: some interference with activity & severe: prevented daily routine activity. Vomiting: mild: 1-2 times in 24h, moderate: > 2 times in 24h, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h & severe: 6 or more loose stools in 24h. Except fever, G4=ER visit/hospitalisation. G4 events classified by investigator/medically qualified person. Exact 95% CI based on Clopper & Pearson method. Safety population=all participants receiving at least 1 dose of study intervention. N= participants evaluable for this endpoint. n=participants evaluable for specified rows.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination 1 (i.e. third dose for Group 1b and fourth dose for Groups 2b and 3b)

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1b: 2 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB: Group 3b: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	218	986	
Units: Percentage of participants				
number (confidence interval 95%)				
Fever: Any (n=13, 218, 986)	0 (0.0 to 24.7)	6.9 (3.9 to 11.1)	5.3 (4.0 to 6.9)	
Fever: ≥ 38.0 to 38.4 deg C (n=13, 218, 986)	0 (0.0 to 24.7)	1.8 (0.5 to 4.6)	1.5 (0.9 to 2.5)	
Fever: > 38.4 to 38.9 deg C (n=13, 218, 986)	0 (0.0 to 24.7)	3.2 (1.3 to 6.5)	2.0 (1.2 to 3.1)	
Fever: > 38.9 to 40.0 deg C (n=13, 218, 986)	0 (0.0 to 24.7)	1.4 (0.3 to 4.0)	1.4 (0.8 to 2.4)	
Fever: > 40.0 deg C (n=13, 218, 986)	0 (0.0 to 24.7)	0.5 (0.0 to 2.5)	0.2 (0.0 to 0.7)	
Fever: Unknown ((n=13, 218, 986)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0.1 (0.0 to 0.6)	

Fatigue: Any (n=13, 217, 976)	30.8 (9.1 to 61.4)	31.3 (25.2 to 38.0)	29.0 (26.2 to 32.0)
Fatigue: Mild (n=13, 217, 976)	15.4 (1.9 to 45.4)	17.5 (12.7 to 23.2)	17.8 (15.5 to 20.4)
Fatigue: Moderate (n=13, 217, 976)	15.4 (1.9 to 45.4)	12.4 (8.4 to 17.6)	10.7 (8.8 to 12.8)
Fatigue: Severe (n=13, 217, 976)	0 (0.0 to 24.7)	1.4 (0.3 to 4.0)	0.5 (0.2 to 1.2)
Fatigue: Grade 4 (n=13, 217, 976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
Headache: Any (n=13, 217, 976)	7.7 (0.2 to 36.0)	4.1 (1.9 to 7.7)	4.4 (3.2 to 5.9)
Headache: Mild (n=13, 217, 976)	7.7 (0.2 to 36.0)	2.3 (0.8 to 5.3)	3.7 (2.6 to 5.1)
Headache: Moderate (n=13, 217, 976)	0 (0.0 to 24.7)	1.4 (0.3 to 4.0)	0.7 (0.3 to 1.5)
Headache: Severe (n=13, 217, 976)	0 (0.0 to 24.7)	0.5 (0.0 to 2.5)	0 (0.0 to 0.4)
Headache: Grade 4 (n=13, 217, 976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
Chills: Any (n=13, 217, 976)	0 (0.0 to 24.7)	4.6 (2.2 to 8.3)	2.5 (1.6 to 3.6)
Chills: Mild (n=13, 217, 976)	0 (0.0 to 24.7)	3.2 (1.3 to 6.5)	1.8 (1.1 to 2.9)
Chills: Moderate (n=13, 217, 976)	0 (0.0 to 24.7)	1.4 (0.3 to 4.0)	0.6 (0.2 to 1.3)
Chills: Severe (n=13, 217, 976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
Chills: Grade 4 (n=13, 217, 976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
Vomiting: Any (n=13, 217, 976)	7.7 (0.2 to 36.0)	5.1 (2.6 to 8.9)	4.8 (3.6 to 6.4)
Vomiting: Mild (n=13, 217, 976)	7.7 (0.2 to 36.0)	3.2 (1.3 to 6.5)	4.0 (2.9 to 5.4)
Vomiting: Moderate (n=13, 217, 976)	0 (0.0 to 24.7)	1.8 (0.5 to 4.7)	0.8 (0.4 to 1.6)
Vomiting: Severe (n=13, 217, 976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
Vomiting: Grade 4 (n=13, 217, 976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
Diarrhea: Any (n=13, 217, 976)	0 (0.0 to 24.7)	5.1 (2.6 to 8.9)	7.0 (5.5 to 8.7)
Diarrhea: Mild (n=13, 217, 976)	0 (0.0 to 24.7)	4.1 (1.9 to 7.7)	6.0 (4.6 to 7.7)
Diarrhea: Moderate (n=13, 217, 976)	0 (0.0 to 24.7)	0.9 (0.1 to 3.3)	0.8 (0.4 to 1.6)
Diarrhea: Severe (n=13, 217, 976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0.1 (0.0 to 0.6)
Diarrhea: Grade 4 (n=13, 217, 976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
New or worsened muscle pain:Any(n=13,217,976)	0 (0.0 to 24.7)	3.2 (1.3 to 6.5)	2.0 (1.3 to 3.1)
New or worsened muscle pain:Mild(n=13,217,976)	0 (0.0 to 24.7)	2.3 (0.8 to 5.3)	1.2 (0.6 to 2.1)
New or worsened muscle pain:Moderate(n=13,217,976)	0 (0.0 to 24.7)	0.9 (0.1 to 3.3)	0.8 (0.4 to 1.6)
New or worsened muscle pain:Severe(n=13,217,976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
New or worsened muscle pain:Grade4(n=13,217,976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
New or worsened joint pain:Any(n=13,217,976)	0 (0.0 to 24.7)	0.9 (0.1 to 3.3)	0.9 (0.4 to 1.7)
New or worsened joint pain:Mild(n=13,217,976)	0 (0.0 to 24.7)	0.9 (0.1 to 3.3)	0.7 (0.3 to 1.5)
New or worsened joint pain:Moderate(n=13,217,976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0.2 (0.0 to 0.7)
New or worsened joint pain:Severe(n=13,217,976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)
New or worsened joint pain:Grade 4(n=13,217,976)	0 (0.0 to 24.7)	0 (0.0 to 1.7)	0 (0.0 to 0.4)

Statistical analyses

Primary: SSB: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination 2 in Participants Aged ≥ 2 to < 5 Years: Group 1b Only

End point title	SSB: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination 2 in Participants Aged ≥ 2 to < 5 Years: Group 1b Only ^{[18][19]}
-----------------	--

End point description:

Systemic events recorded by participants/parents/legal guardians in e-diary. Fever: oral temperature ≥ 38.0 deg C and categorised as ≥ 38.0 - 38.4 deg C, > 38.4 - 38.9 deg C, > 38.9 - 40.0 deg C & > 40.0 deg C. Fatigue, headache, chills, new/worsened muscle pain & new/worsened joint pain: mild: did not interfere with activity, moderate: some interference with activity & severe: prevented daily routine activity. Vomiting: mild: 1-2 times in 24h, moderate: > 2 times in 24h, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h & severe: 6 or more loose stools in 24h. Except fever, G4=ER visit/hospitalisation. G4 events classified by investigator/medically qualified person. Exact 95% CI based on Clopper & Pearson method. Safety population=all participants receiving at least 1 dose of study intervention. N= participants evaluable for this endpoint. n=participants evaluable for specified rows.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination 2 (i.e third dose for Group 1b)

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1b: 2 prior doses of BNT162b2			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Percentage of participants				
number (confidence interval 95%)				
Fever: ≥ 38.0 deg C (n=11)	0 (0.0 to 28.5)			
Fever: 38.0 to 38.4 deg C (n=11)	0 (0.0 to 28.5)			
Fever: > 38.4 to 38.9 deg C (n=11)	0 (0.0 to 28.5)			
Fever: > 38.9 to 40.0 deg C (n=11)	0 (0.0 to 28.5)			
Fever: > 40.0 deg C (n=11)	0 (0.0 to 28.5)			
Fatigue: Any (n=12)	33.3 (9.9 to 65.1)			
Fatigue: Mild (n=12)	16.7 (2.1 to 48.4)			
Fatigue: Moderate (n=12)	16.7 (2.1 to 48.4)			
Fatigue: Severe (n=12)	0 (0.0 to 26.5)			
Fatigue: Grade 4 (n=12)	0 (0.0 to 26.5)			
Headache: Any (n=11)	0 (0.0 to 28.5)			
Headache: Mild (n=11)	0 (0.0 to 28.5)			
Headache: Moderate (n=11)	0 (0.0 to 28.5)			
Headache: Severe (n=11)	0 (0.0 to 28.5)			
Headache: Grade 4 (n=11)	0 (0.0 to 28.5)			
Chills: Any (n=11)	0 (0.0 to 28.5)			

Chills: Mild (n=11)	0 (0.0 to 28.5)			
Chills: Moderate (n=11)	0 (0.0 to 28.5)			
Chills: Severe (n=11)	0 (0.0 to 28.5)			
Chills: Grade 4 (n=11)	0 (0.0 to 28.5)			
Vomiting: Any (n=11)	9.1 (0.2 to 41.3)			
Vomiting: Mild (n=11)	9.1 (0.2 to 41.3)			
Vomiting: Moderate (n=11)	0 (0.0 to 28.5)			
Vomiting: Severe (n=11)	0 (0.0 to 28.5)			
Vomiting: Grade 4 (n=11)	0 (0.0 to 28.5)			
Diarrhea: Any (n=11)	9.1 (0.2 to 41.3)			
Diarrhea: Mild (n=11)	9.1 (0.2 to 41.3)			
Diarrhea: Moderate (n=11)	0 (0.0 to 28.5)			
Diarrhea: Severe (n=11)	0 (0.0 to 28.5)			
Diarrhea: Grade 4 (n=11)	0 (0.0 to 28.5)			
New or worsened muscle pain: Any (n=11)	0 (0.0 to 28.5)			
New or worsened muscle pain: Mild (n=11)	0 (0.0 to 28.5)			
New or worsened muscle pain: Moderate (n=11)	0 (0.0 to 28.5)			
New or worsened muscle pain: Severe (n=11)	0 (0.0 to 28.5)			
New or worsened muscle pain: Grade 4 (n=11)	0 (0.0 to 28.5)			
New or worsened joint pain: Any (n=11)	0 (0.0 to 28.5)			
New or worsened joint pain: Mild (n=11)	0 (0.0 to 28.5)			
New or worsened joint pain: Moderate (n=11)	0 (0.0 to 28.5)			
New or worsened joint pain: Severe (n=11)	0 (0.0 to 28.5)			
New or worsened joint pain: Grade 4 (n=11)	0 (0.0 to 28.5)			

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants Reporting AEs From the First Study Vaccination to 1 Month After Study Vaccination 1 in Participants Aged ≥ 2 to < 5 Years

End point title	SSB: Percentage of Participants Reporting AEs From the First Study Vaccination to 1 Month After Study Vaccination 1 in Participants Aged ≥ 2 to < 5 Years ^{[20][21]}
-----------------	--

End point description:

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this endpoint. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination on Day 1 up to 1 month after study vaccination 1 (i.e. third dose for Group 1b and fourth dose for Groups 2b and 3b)

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1b: 2 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB: Group 3b: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	13	218	989	
Units: Percentage of participants				
number (not applicable)	0	4.6	6.6	

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants Reporting AEs From the Second Study Vaccination to 1 Month After Study Vaccination 2 in Participants Aged ≥ 2 to <5 Years: Group 1b Only

End point title	SSB: Percentage of Participants Reporting AEs From the Second Study Vaccination to 1 Month After Study Vaccination 2 in Participants Aged ≥ 2 to <5 Years: Group 1b Only ^[22] ^[23]
-----------------	---

End point description:

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this endpoint. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention. N=participants evaluable for this endpoint. This endpoint is reported for Group 1b only as only participants from Group 1b received two vaccinations in the study.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination 2 up to 1 month after study vaccination 2

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1b: 2 prior doses of BNT162b2			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Percentage of participants				
number (confidence interval 95%)	8.3 (0.2 to 38.5)			

Statistical analyses

No statistical analyses for this end point

Primary: SSB: Percentage of Participants Reporting SAEs From the First Study Vaccination to 6 Months After Last Study Vaccination in Participants Aged ≥ 2 to < 5 Years

End point title	SSB: Percentage of Participants Reporting SAEs From the First Study Vaccination to 6 Months After Last Study Vaccination in Participants Aged ≥ 2 to < 5 Years ^[24] ^[25]
-----------------	---

End point description:

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation. Safety population included all participants who received at least 1 dose of the study intervention. N= participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

From first study vaccination on Day 1 up to 6 months after last study vaccination

Notes:

[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1b: 2 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB: Group 3b: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	218	989	
Units: Percentage of participants				
number (not applicable)	0	0	0.4	

Statistical analyses

No statistical analyses for this end point

Primary: SSB: GMR Based on Geometric Mean Titers of Severe Acute Respiratory

Syndrome Coronavirus 2 (SARSCoV2) Omicron (BA.4/BA.5)–Neutralizing Titers at 1 Month After Dose 4 for Group 2 and at 1 Month After Dose 3 for C4591007 Phase 2/3 Participants

End point title	SSB: GMR Based on Geometric Mean Titers of Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2) Omicron (BA.4/BA.5)–Neutralizing Titers at 1 Month After Dose 4 for Group 2 and at 1 Month After Dose 3 for C4591007 Phase 2/3 Participants ^[26]
-----------------	---

End point description:

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the least square means and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status & vaccine group as covariates. Assay results below the LLOQ were set to 0.5*LLOQ. Evaluable immunogenicity population included all eligible participants who received the study intervention to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, had no other important protocol deviations as determined by clinician. Results are presented for per-protocol subset which included random sample of 240 participants selected from the full group & comprised the same percentages of participants in each age group and baseline SARS-CoV-2 infection status group as the full group. 'N' = participants evaluable.

End point type	Primary
----------------	---------

End point timeframe:

1 month after Dose 4 for Group 2 and 1 month after Dose 3 for C4591007 control arm

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB Historical cohort: C4591007 BNT162b2 ≥6 months to <2 years	SSB Historical cohort: C4591007 BNT162b2 3 mcg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	62	161	71	167
Units: Titers				
geometric mean (confidence interval 95%)	1664.4 (1339.3 to 2068.3)	1920.7 (1661.9 to 2219.8)	1031.3 (842.0 to 1263.3)	901.8 (782.4 to 1039.5)

Statistical analyses

Statistical analysis title	Geometric Mean Ratio
----------------------------	----------------------

Statistical analysis description:

GMRs and 2-sided CIs were calculated by exponentiating the difference of LSMeans for the assay and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status, age group and vaccine group as covariates.

Comparison groups	SSB: Group 2b: 3 prior doses of BNT162b2 v SSB Historical cohort: C4591007 BNT162b2 3 mcg
-------------------	---

Number of subjects included in analysis	328
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Geometric Mean Ratio
Point estimate	2.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.73
upper limit	2.62

Statistical analysis title	Geometric Mean Ratio
-----------------------------------	----------------------

Statistical analysis description:

GMRs and 2-sided CIs were calculated by exponentiating the difference of LSMeans for the assay and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status, age group and vaccine group as covariates.

Comparison groups	SSB: Group 2a: 3 prior doses of BNT162b2 v SSB Historical cohort:C4591007 BNT162b2 >=6 months to<2 years
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Geometric Mean Ratio
Point estimate	1.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.2
upper limit	2.18

Primary: SSB: Percentage of Participants With Seroresponse to the Omicron (BA.4/BA.5)–Strain at 1 Month After Dose 4 for Group 2 and at 1 Month After Dose 3 for C4591007 Phase 2/3 Participants

End point title	SSB: Percentage of Participants With Seroresponse to the Omicron (BA.4/BA.5)–Strain at 1 Month After Dose 4 for Group 2 and at 1 Month After Dose 3 for C4591007 Phase 2/3 Participants ^[27]
-----------------	---

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 4 for C4591048 Substudy B Group 2 and before Dose 3 for C4591007). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination assay result of $\geq 4 \times \text{LLOQ}$ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Percentage of participants achieving seroresponse at 1 month after study vaccination was reported in this endpoint. Evaluable immunogenicity population was analyzed. Results were presented for per-protocol subset which included a random sample of 240 participants selected from the full group and comprised of the same percentage of participants in each age group and baseline SARS-CoV-2 infection status group as the full group. 'N'=participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

1 month after Dose 4 for Group 2 and 1 month after Dose 3 for C4591007 control arm

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB Historical cohort: C4591007 BNT162b2 ≥ 6 months to < 2 years	SSB Historical cohort: C4591007 BNT162b2 3 mcg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	62	161	71	167
Units: Percentage of participants				
number (confidence interval 95%)	54.8 (41.7 to 67.5)	71.4 (63.8 to 78.3)	42.3 (30.6 to 54.6)	53.9 (46.0 to 61.6)

Statistical analyses

Statistical analysis title	Percentages of Participants With Seroresponse
Statistical analysis description: Adjusted difference in proportion based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category ($< \text{median}$, $\geq \text{median}$), expressed as a percentage (bivalent BNT162b2 [original/Omi BA.4/BA.5] 3 mcg - BNT162b2 3 mcg).	
Comparison groups	SSB: Group 2a: 3 prior doses of BNT162b2 v SSB Historical cohort: C4591007 BNT162b2 ≥ 6 months to < 2 years
Number of subjects included in analysis	133
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[28]
Parameter estimate	Percentage Difference
Point estimate	16.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	31.67

Notes:

[28] - Noninferiority was established if the lower bound of the 2-sided 95% CI for the difference in percentage was greater than -5%.

Statistical analysis title	Percentages of Participants With Seroresponse
Statistical analysis description: Adjusted difference in proportion based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category ($< \text{median}$, $\geq \text{median}$), expressed as a percentage (bivalent BNT162b2 [original/Omi BA.4/BA.5] 3 mcg - BNT162b2 3 mcg).	
Comparison groups	SSB: Group 2b: 3 prior doses of BNT162b2 v SSB Historical cohort: C4591007 BNT162b2 3 mcg

Number of subjects included in analysis	328
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[29]
Parameter estimate	Percentage Difference
Point estimate	21.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.59
upper limit	31.15

Notes:

[29] - Noninferiority was established if the lower bound of the 2-sided 95% CI for the difference in percentage was greater than -5%.

Primary: SSC: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination in Participants Aged ≥ 6 Months to < 2 Years

End point title	SSC: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination in Participants Aged ≥ 6 Months to < 2 Years ^{[30][31]}
-----------------	--

End point description:

Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after study vaccination. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (≥ 0.5 to 2.0 cm), moderate (> 2.0 to 7.0 cm), severe (> 7.0 cm) and G4 (necrosis [redness and swelling] or exfoliative dermatitis [redness]). Tenderness at injection site was graded as mild (hurts if gently touched), moderate (hurts if gently touched with crying), severe (causes limitation of limb movement) & G4 ER visit or hospitalisation. G4 were classified by investigator or medically qualified person. Percentage of participants with local reactions within 7 days after study vaccination and associated 2-sided 95% CI based on Clopper and Pearson method is reported. Safety population=all participants receiving at least 1 dose of study intervention.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination

Notes:

[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	19		
Units: Percentage of participants				
number (confidence interval 95%)				
Redness: Any	23.5 (6.8 to 49.9)	21.1 (6.1 to 45.6)		
Redness: Mild	17.6 (3.8 to 43.4)	21.1 (6.1 to 45.6)		
Redness: Moderate	5.9 (0.1 to 28.7)	0 (0.0 to 17.6)		
Redness: Severe	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Redness: Grade 4	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Swelling: Any	0 (0.0 to 19.5)	0 (0.0 to 17.6)		

Swelling: Mild	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Swelling: Moderate	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Swelling: Severe	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Swelling: Grade 4	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Tenderness at the injection site: Any	5.9 (0.1 to 28.7)	15.8 (3.4 to 39.6)		
Tenderness at the injection site: Mild	5.9 (0.1 to 28.7)	15.8 (3.4 to 39.6)		
Tenderness at the injection site: Moderate	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Tenderness at the injection site: Severe	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Tenderness at the injection site: Grade 4	0 (0.0 to 19.5)	0 (0.0 to 17.6)		

Statistical analyses

No statistical analyses for this end point

Primary: SSC: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination in Participants Aged ≥ 6 Months to < 2 Years

End point title	SSC: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination in Participants Aged ≥ 6 Months to < 2 Years ^[32] ^[33]
-----------------	--

End point description:

Systemic events recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after study vaccination. Fever: oral temperature ≥ 38.0 deg C categorised as ≥ 38.0 to 38.4 deg C, > 38.4 to 38.9 deg C, > 38.9 to 40.0 deg C & > 40.0 deg C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake), severe (refusal to feed). Drowsiness: mild (increased or prolonged sleeping bouts), moderate (slightly subdued interfering with daily activity), severe (disabling; not interested in usual daily activity). Irritability: mild (easily consolable), moderate (requiring increased attention), severe (disabling; not interested in usual daily activity). G4 for all events except fever: ER visit/hospitalisation & were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method. Safety population = all participants receiving at least 1 dose of study intervention.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination

Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	19		
Units: Percentage of participants				
number (confidence interval 95%)				
Fever: Any	17.6 (3.8 to 43.4)	5.3 (0.1 to 26.0)		

Fever: ≥ 38.0 to 38.4 deg C	11.8 (1.5 to 36.4)	0 (0.0 to 17.6)		
Fever: >38.4 to 38.9 deg C	5.9 (0.1 to 28.7)	5.3 (0.1 to 26.0)		
Fever: >38.9 to 40.0 deg C	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Fever: >40.0 deg C	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Decreased appetite: Any	23.5 (6.8 to 49.9)	15.8 (3.4 to 39.6)		
Decreased appetite: Mild	23.5 (6.8 to 49.9)	15.8 (3.4 to 39.6)		
Decreased appetite: Moderate	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Decreased appetite: Severe	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Decreased appetite: Grade 4	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Drowsiness: Any	29.4 (10.3 to 56.0)	26.3 (9.1 to 51.2)		
Drowsiness: Mild	17.6 (3.8 to 43.4)	21.1 (6.1 to 45.6)		
Drowsiness: Moderate	11.8 (1.5 to 36.4)	5.3 (0.1 to 26.0)		
Drowsiness: Severe	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Drowsiness: Grade 4	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Irritability: Any	47.1 (23.0 to 72.2)	73.7 (48.8 to 90.9)		
Irritability: Mild	29.4 (10.3 to 56.0)	21.1 (6.1 to 45.6)		
Irritability: Moderate	17.6 (3.8 to 43.4)	52.6 (28.9 to 75.6)		
Irritability: Severe	0 (0.0 to 19.5)	0 (0.0 to 17.6)		
Irritability: Grade 4	0 (0.0 to 19.5)	0 (0.0 to 17.6)		

Statistical analyses

No statistical analyses for this end point

Primary: SSC: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination in Participants Aged ≥ 6 Months to <2 Years

End point title	SSC: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination in Participants Aged ≥ 6 Months to <2 Years ^[34] ^[35]
-----------------	--

End point description:

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this endpoint. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination on Day 1 up to 1 month after study vaccination

Notes:

[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all

the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	19		
Units: Percentage of participants				
number (not applicable)	11.8	15.8		

Statistical analyses

No statistical analyses for this end point

Primary: SSC: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination in Participants Aged ≥ 6 Months to < 2 Years

End point title	SSC: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination in Participants Aged ≥ 6 Months to < 2 Years ^[36] ^[37]
-----------------	---

End point description:

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation. Safety population included all participants who received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination on Day 1 up to 6 months after study vaccination

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	19		
Units: Percentage of participants				
number (not applicable)	0	0		

Statistical analyses

Primary: SSC: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination in Participants Aged ≥ 2 to < 5 Years

End point title	SSC: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination in Participants Aged ≥ 2 to < 5 Years ^{[38][39]}
-----------------	---

End point description:

Local reactions recorded by participants/parents/legal guardians in e-diary. Redness & swelling recorded in mdu converted to cm. 1 mdu = 0.5 cm & graded mild: (> 0.5 to 2.0 cm), moderate: > 2.0 to 7.0 cm, severe: > 7.0 cm, G4: necrosis/exfoliative dermatitis (redness) & necrosis (swelling). Pain at injection site graded mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity & G4: ER visit/hospitalisation. G4 classified by investigator/medically qualified person. Percentage of participants with local reactions within 7 days after study vaccination and associated 2-sided 95% CI based on Clopper and Pearson method. Safety population = all participants receiving at least 1 dose of study intervention. Number of subjects analyzed = participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination

Notes:

[38] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	30		
Units: Percentage of participants				
number (confidence interval 95%)				
Redness: Any	6.3 (0.8 to 20.8)	3.3 (0.1 to 17.2)		
Redness: Mild	6.3 (0.8 to 20.8)	3.3 (0.1 to 17.2)		
Redness: Moderate	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Redness: Severe	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Redness: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Swelling: Any	6.3 (0.8 to 20.8)	0 (0.0 to 11.6)		
Swelling: Mild	6.3 (0.8 to 20.8)	0 (0.0 to 11.6)		
Swelling: Moderate	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Swelling: Severe	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Swelling: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Pain at the injection site: Any	31.3 (16.1 to 50.0)	26.7 (12.3 to 45.9)		
Pain at the injection site: Mild	28.1 (13.7 to 46.7)	26.7 (12.3 to 45.9)		
Pain at the injection site: Moderate	3.1 (0.1 to 16.2)	0 (0.0 to 11.6)		
Pain at the injection site: Severe	0 (0.0 to 10.9)	0 (0.0 to 11.6)		

Pain at the injection site: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
-------------------------------------	-----------------	-----------------	--	--

Statistical analyses

No statistical analyses for this end point

Primary: SSC: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination in Participants Aged ≥ 2 to < 5 Years

End point title	SSC: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination in Participants Aged ≥ 2 to < 5 Years ^{[40][41]}
-----------------	---

End point description:

Systemic events recorded by participants/parents/legal guardians in e-diary. Fever: oral temperature ≥ 38.0 deg C and categorised as ≥ 38.0 -38.4 deg C, > 38.4 -38.9 deg C, > 38.9 -40.0 deg C & > 40.0 deg C. Fatigue, headache, chills, new/worsened muscle pain & new/worsened joint pain: mild: did not interfere with activity, moderate: some interference with activity & severe: prevented daily routine activity. Vomiting: mild: 1-2 times in 24h, moderate: > 2 times in 24h, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h & severe: 6 or more loose stools in 24h. Except fever, G4=ER visit/hospitalisation. G4 events classified by investigator/medically qualified person. Exact 95% CI based on Clopper & Pearson method. Safety population=all participants receiving at least 1 dose of study intervention.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination

Notes:

[40] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	30		
Units: Percentage of participants				
number (confidence interval 95%)				
Fever: Any	25.0 (11.5 to 43.4)	10.0 (2.1 to 26.5)		
Fever: 38.0 to 38.4 deg C	6.3 (0.8 to 20.8)	6.7 (0.8 to 22.1)		
Fever: > 38.4 to 38.9 deg C	12.5 (3.5 to 29.0)	0 (0.0 to 11.6)		
Fever: > 38.9 to 40.0 deg C	6.3 (0.8 to 20.8)	3.3 (0.1 to 17.2)		
Fever: > 40.0 deg C	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Fatigue: Any	40.6 (23.7 to 59.4)	36.7 (19.9 to 56.1)		
Fatigue: Mild	12.5 (3.5 to 29.0)	23.3 (9.9 to 42.3)		

Fatigue: Moderate	21.9 (9.3 to 40.0)	13.3 (3.8 to 30.7)		
Fatigue: Severe	6.3 (0.8 to 20.8)	0 (0.0 to 11.6)		
Fatigue: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Headache: Any	12.5 (3.5 to 29.0)	3.3 (0.1 to 17.2)		
Headache: Mild	6.3 (0.8 to 20.8)	3.3 (0.1 to 17.2)		
Headache: Moderate	6.3 (0.8 to 20.8)	0 (0.0 to 11.6)		
Headache: Severe	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Headache: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Chills: Any	12.5 (3.5 to 29.0)	3.3 (0.1 to 17.2)		
Chills: Mild	9.4 (2.0 to 25.0)	0 (0.0 to 11.6)		
Chills: Moderate	3.1 (0.1 to 16.2)	3.3 (0.1 to 17.2)		
Chills: Severe	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Chills: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Vomiting: Any	9.4 (2.0 to 25.0)	6.7 (0.8 to 22.1)		
Vomiting: Mild	6.3 (0.8 to 20.8)	6.7 (0.8 to 22.1)		
Vomiting: Moderate	3.1 (0.1 to 16.2)	0 (0.0 to 11.6)		
Vomiting: Severe	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Vomiting: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Diarrhea: Any	6.3 (0.8 to 20.8)	3.3 (0.1 to 17.2)		
Diarrhea: Mild	3.1 (0.1 to 16.2)	0 (0.0 to 11.6)		
Diarrhea: Moderate	3.1 (0.0 to 10.9)	3.3 (0.1 to 17.2)		
Diarrhea: Severe	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
Diarrhea: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
New or worsened muscle pain: Any	9.4 (2.0 to 25.0)	6.7 (0.8 to 22.1)		
New or worsened muscle pain: Mild	6.3 (0.8 to 20.8)	3.3 (0.1 to 17.2)		
New or worsened muscle pain: Moderate	3.1 (0.1 to 16.2)	3.3 (0.1 to 17.2)		
New or worsened muscle pain: Severe	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
New or worsened muscle pain: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
New or worsened joint pain: Any	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
New or worsened joint pain: Mild	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
New or worsened joint pain: Moderate	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
New or worsened joint pain: Severe	0 (0.0 to 10.9)	0 (0.0 to 11.6)		
New or worsened joint pain: Grade 4	0 (0.0 to 10.9)	0 (0.0 to 11.6)		

Statistical analyses

No statistical analyses for this end point

Primary: SSC: Percentage of Participants Reporting AEs Within 1 Month After Study Vaccination in Participants Aged ≥ 2 to < 5 Years

End point title	SSC: Percentage of Participants Reporting AEs Within 1 Month After Study Vaccination in Participants Aged ≥ 2 to < 5 Years ^{[42][43]}
-----------------	---

End point description:

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this endpoint. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination on Day 1 up to 1 month after study vaccination

Notes:

[42] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	30		
Units: Percentage of participants				
number (not applicable)	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: SSC: Geometric Mean Titers of SARSCoV2 Omicron (BA.4/BA.5)–Neutralizing Titers Before Vaccination and 1 Month After Vaccination

End point title	SSC: Geometric Mean Titers of SARSCoV2 Omicron (BA.4/BA.5)–Neutralizing Titers Before Vaccination and 1 Month After Vaccination ^{[44][45]}
-----------------	---

End point description:

GMT of SARS-CoV-2 Omicron strain–neutralizing titers before vaccination and 1 month after the study vaccination was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5*LLOQ. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

before vaccination and 1 month after study vaccination

Notes:

[44] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	14	30	30
Units: Titers				
geometric mean (confidence interval 95%)				
Pre-vaccination (n= 9, 14, 27, 28)	370.6 (62.7 to 2190.9)	225.8 (66.7 to 763.7)	199.3 (102.4 to 387.7)	312.6 (161.5 to 605.0)
1 month after vaccination (n= 11, 14, 30, 30)	3059.7 (767.0 to 12205.5)	2866.8 (772.8 to 10634.9)	3536.4 (2044.2 to 6117.9)	7155.7 (3926.9 to 13039.1)

Statistical analyses

No statistical analyses for this end point

Primary: SSC: Percentage of Participants Reporting SAEs Within 6 Months After Study Vaccination in Participants Aged ≥ 2 to < 5 Years

End point title	SSC: Percentage of Participants Reporting SAEs Within 6 Months After Study Vaccination in Participants Aged ≥ 2 to < 5 Years ^{[46][47]}
-----------------	---

End point description:

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation. Safety population included all participants who received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination on Day 1 up to 6 months after study vaccination

Notes:

[46] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	30		
Units: Percentage of participants				
number (not applicable)	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: SSC: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers From Study Vaccination to 1 Month After Vaccination

End point title	SSC: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers From Study Vaccination to 1 Month After Vaccination ^[48] ^[49]
-----------------	--

End point description:

GMFR of SARS-CoV-2 omicron BA.4/BA.5-neutralizing titers at 1 month after study vaccination was reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ in the analysis. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N' = participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination on Day 1 up to 1 month after study vaccination

Notes:

[48] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	14	27	28
Units: Fold rise				
geometric mean (confidence interval 95%)	8.3 (2.5 to 27.3)	12.7 (6.1 to 26.3)	17.4 (11.1 to 27.4)	24.4 (14.9 to 40.0)

Statistical analyses

No statistical analyses for this end point

Primary: SSC:Percentages of Participants With Seroresponse to the Omicron (BA.4/BA.5)– Neutralizing Titers at 1 Month After Study Vaccination

End point title	SSC:Percentages of Participants With Seroresponse to the Omicron (BA.4/BA.5)– Neutralizing Titers at 1 Month After Study Vaccination ^{[50][51]}
-----------------	--

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before the study vaccination). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination assay result of $\geq 4 \times$ LLOQ was considered a seroresponse. Exact 2-sided 95% CI, based on the Clopper and Pearson method. Percentage of participants achieving seroresponse at 1 month after study vaccination was reported in this endpoint. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

1 Month after study vaccination

Notes:

[50] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	14	27	28
Units: Percentage of participants				
number (confidence interval 95%)	55.6 (21.2 to 86.3)	78.6 (49.2 to 95.3)	85.2 (66.3 to 95.8)	92.9 (76.5 to 99.1)

Statistical analyses

No statistical analyses for this end point

Primary: SSC:Geometric Mean Titers of SARSCoV2 Reference-Strain-Neutralizing Titers Before Vaccination and 1 Month After Vaccination

End point title	SSC:Geometric Mean Titers of SARSCoV2 Reference-Strain-Neutralizing Titers Before Vaccination and 1 Month After Vaccination ^{[52][53]}
-----------------	---

End point description:

GMT of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month after study vaccination was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers & the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to $0.5 \times$ LLOQ. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.n=participants evaluable for specified rows.

End point type	Primary
----------------	---------

End point timeframe:

Before study vaccination and 1 Month after study vaccination

Notes:

[52] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	14	30	30
Units: Titers				
geometric mean (confidence interval 95%)				
Before Vaccination (n=9,14,26,28)	1638.1 (690.2 to 3887.9)	1041.5 (641.3 to 1691.5)	1536.5 (952.7 to 2477.9)	2263.8 (1502.2 to 3411.5)
1 Month After Vaccination (n=11, 14, 30, 30)	7698.7 (4384.4 to 13518.6)	8443.8 (5696.8 to 12515.4)	9389.0 (6314.3 to 13961.1)	16541.7 (12265.4 to 22309.0)

Statistical analyses

No statistical analyses for this end point

Primary: SSC:GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Study Vaccination to 1 Month After Vaccination

End point title	SSC:GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Study Vaccination to 1 Month After Vaccination ^[54] ^[55]
-----------------	---

End point description:

GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month after study vaccination was reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5* LLOQ in the analysis. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

1 Month after study vaccination

Notes:

[54] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	14	26	28
Units: Fold rise				
geometric mean (confidence interval 95%)	5.4 (3.1 to 9.6)	8.1 (5.2 to 12.6)	5.7 (3.4 to 9.5)	7.4 (4.9 to 11.2)

Statistical analyses

No statistical analyses for this end point

Primary: SSC: Percentages of Participants With Seroresponse to the SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After Study Vaccination

End point title	SSC: Percentages of Participants With Seroresponse to the SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After Study Vaccination ^[56] ^[57]
-----------------	--

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before study vaccination). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination assay result of $\geq 4 \times \text{LLOQ}$ was considered a seroresponse. Exact 2-sided 95% CI, based on the Clopper and Pearson method. Percentage of participants achieving seroresponse at 1 month after study vaccination was reported in this endpoint. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

1 Month After Study Vaccination

Notes:

[56] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSC; hence, only arms for SSC were included.

End point values	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2	SSC: Group 2b: 3 prior doses of BNT162b2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	14	26	28
Units: Percentage of participants				
number (confidence interval 95%)	55.6 (21.2 to 86.3)	85.7 (57.2 to 98.2)	76.9 (56.4 to 91.0)	67.9 (47.6 to 84.1)

Statistical analyses

Primary: SSD: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination

End point title	SSD: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination ^{[58][59]}
-----------------	--

End point description:

Local reactions recorded by participants/parents/legal guardians in electronic diary(e-diary).Redness&swelling recorded in measuring device units(mdu)converted to centimeter(cm).1 mdu=0.5 cm&graded mild:(greater than[>]0.5 to 2.0cm),moderate:>2.0 to 7.0cm,severe:>7.0 cm,Grade 4(G4): necrosis/exfoliative dermatitis(redness)&necrosis(swelling).Pain at injection site graded mild:did not interfere with daily activity,moderate:interfered with daily activity,severe: prevented daily activity&G4:emergency room[ER]visit/hospitalisation.G4 classified by investigator/medically qualified person.Percentage of participants with local reactions within 7days after study vaccination and associated 2-sided 95% confidence interval(CI) based on Clopper and Pearson method.Safety population=all participants receiving at least 1dose of study intervention.Number of Participants Analysed(N)= participants evaluable.99999=data could not be generated since it was not part of specified analysis in the protocol.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination

Notes:

[58] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD Group 3:Participants from study C4591007 Phase 1	SSD: Group 1: 2 prior doses of BNT162b2	SSD: Group 2: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	19	2	111	
Units: Percentage of participants				
number (confidence interval 95%)				
Redness: Any	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	7.2 (3.2 to 13.7)	
Redness: Mild	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	4.5 (1.5 to 10.2)	
Redness: Moderate	0 (0.0 to 17.6)	0 (-99999 to 99999)	2.7 (0.6 to 7.7)	
Redness: Severe	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	
Redness: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	
Swelling: Any	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	4.5 (1.5 to 10.2)	
Swelling: Mild	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	0.9 (0.0 to 4.9)	
Swelling: Moderate	0 (0.0 to 17.6)	0 (-99999 to 99999)	3.6 (1.0 to 9.0)	
Swelling: Severe	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	
Swelling: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	

Pain at the injection site: Any	68.4 (43.4 to 87.4)	0 (-99999 to 99999)	64.0 (54.3 to 72.9)	
Pain at the injection site: Mild	52.6 (28.9 to 75.6)	50.0 (-99999 to 99999)	45.0 (35.6 to 54.8)	
Pain at the injection site: Moderate	15.8 (3.4 to 39.6)	0 (-99999 to 99999)	18.9 (12.1 to 27.5)	
Pain at the injection site: Severe	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	
Pain at the injection site: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	

Statistical analyses

No statistical analyses for this end point

Primary: SSD: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination

End point title	SSD: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination ^[60] ^[61]
-----------------	--

End point description:

Systemic events recorded by participants/parents/legal guardians in e-diary. Fever: oral temperature ≥ 38.0 degree Celsius(deg C) & categorised as ≥ 38.0 -38.4 deg C, >38.4 -38.9 deg C, >38.9 -40.0 deg C & >40.0 deg C. Fatigue, headache, chills, new/worsened muscle pain & new/worsened joint pain: mild: did not interfere with activity, moderate: some interference with activity & severe: prevented daily routine activity. Vomiting: mild: 1-2 times in 24 hours(h), moderate: >2 times in 24h, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h & severe: 6 or more loose stools in 24h. Except fever, G4=ER visit/hospitalisation. G4 events classified by investigator/medically qualified person. Exact 95% CI based on Clopper & Pearson method. Safety population=all participants receiving at least 1 dose of study intervention. N= participants evaluable for this endpoint. 99999=data could not be generated since it was not part of specified analysis in the protocol.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination

Notes:

[60] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[61] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD Group 3: Participants from study C4591007 Phase 1	SSD: Group 1: 2 prior doses of BNT162b2	SSD: Group 2: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	19	2	111	
Units: Percentage of participants				
number (confidence interval 95%)				
Fever: Any	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	4.5 (1.5 to 10.2)	
Fever: ≥ 38.0 to 38.4 deg C	0 (0.0 to 17.6)	0 (-99999 to 99999)	1.8 (0.2 to 6.4)	

Fever: >38.4 to 38.9 deg C	5.3 (0.1 to 26.0)	0 (-99999 to 99999)	0.9 (0.0 to 4.9)
Fever: >38.9 to 40.0 deg C	5.3 (0.1 to 26.0)	0 (-99999 to 99999)	1.8 (0.2 to 6.4)
Fever: >40.0 deg C	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Fatigue: Any	57.9 (33.5 to 79.7)	0 (-99999 to 99999)	40.5 (31.3 to 50.3)
Fatigue: Mild	36.8 (16.3 to 61.6)	0 (-99999 to 99999)	23.4 (15.9 to 32.4)
Fatigue: Moderate	15.8 (3.4 to 39.6)	0 (-99999 to 99999)	16.2 (9.9 to 24.4)
Fatigue: Severe	5.3 (0.1 to 26.0)	0 (-99999 to 99999)	0.9 (0.0 to 4.9)
Fatigue: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Headache: Any	36.8 (16.3 to 61.6)	0 (-99999 to 99999)	25.2 (17.5 to 34.4)
Headache: Mild	26.3 (9.1 to 51.2)	0 (-99999 to 99999)	18.0 (11.4 to 26.4)
Headache: Moderate	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	6.3 (2.6 to 12.6)
Headache: Severe	0 (0.0 to 17.6)	0 (-99999 to 99999)	0.9 (0.0 to 4.9)
Headache: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Chills: Any	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	9.0 (4.4 to 15.9)
Chills: Mild	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	6.3 (2.6 to 12.6)
Chills: Moderate (n=302)	0 (0.0 to 17.6)	0 (-99999 to 99999)	2.7 (0.6 to 7.7)
Chills: Severe	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Chills: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Vomiting: Any	0 (0.0 to 17.6)	0 (-99999 to 99999)	3.6 (1.0 to 9.0)
Vomiting: Mild	0 (0.0 to 17.6)	0 (-99999 to 99999)	3.6 (1.0 to 9.0)
Vomiting: Moderate	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Vomiting: Severe	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Vomiting: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Diarrhea: Any	0 (0.0 to 17.6)	0 (-99999 to 99999)	3.6 (1.0 to 9.0)
Diarrhea: Mild	0 (0.0 to 17.6)	0 (-99999 to 99999)	3.6 (1.0 to 9.0)
Diarrhea: Moderate	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Diarrhea: Severe	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
Diarrhea: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)
New or worsened muscle pain: Any	21.1 (6.1 to 45.6)	0 (-99999 to 99999)	13.5 (7.8 to 21.3)
New or worsened muscle pain: Mild	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	7.2 (3.2 to 13.7)
New or worsened muscle pain: Moderate	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	6.3 (2.6 to 12.6)

New or worsened muscle pain: Severe	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	
New or worsened muscle pain: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	
New or worsened joint pain: Any	10.5 (1.3 to 33.1)	0 (-99999 to 99999)	9.0 (4.4 to 15.9)	
New or worsened joint pain: Mild	5.3 (0.1 to 26.0)	0 (-99999 to 99999)	7.2 (3.2 to 13.7)	
New or worsened joint pain: Moderate	5.3 (0.1 to 26.0)	0 (-99999 to 99999)	1.8 (0.2 to 6.4)	
New or worsened joint pain: Severe	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	
New or worsened joint pain: Grade 4	0 (0.0 to 17.6)	0 (-99999 to 99999)	0 (0.0 to 3.3)	

Statistical analyses

No statistical analyses for this end point

Primary: SSD: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Study Vaccination

End point title	SSD: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Study Vaccination ^[62] ^[63]
-----------------	--

End point description:

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this endpoint. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this endpoint. Safety population included all participants who received at least 1 dose of the study intervention. 99999= data could not be generated since it was not part of specified analysis in the protocol.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination on Day 1 up to 1 month after study vaccination

Notes:

[62] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[63] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD Group 3: Participants from study C4591007 Phase 1	SSD: Group 1: 2 prior doses of BNT162b2	SSD: Group 2: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	19	2	113	
Units: Percentage of participants				
number (confidence interval 95%)	15.8 (3.4 to 39.6)	0.0 (-99999 to 99999)	3.5 (1.0 to 8.8)	

Statistical analyses

No statistical analyses for this end point

Primary: SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination

End point title	SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination ^{[64][65]}
-----------------	---

End point description:

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalisation or prolongation of existing hospitalisation. Safety population included all participants who received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

From study vaccination on Day 1 up to 6 months after study vaccination

Notes:

[64] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[65] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD Group 3: Participants from study C4591007 Phase 1	SSD: Group 1: 2 prior doses of BNT162b2	SSD: Group 2: 3 prior doses of BNT162b2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	19	2	113	
Units: Percentage of participants				
number (not applicable)	0	0	0	

Statistical analyses

No statistical analyses for this end point

Primary: SSD: Percentages of Participants With Seroresponse to the Omicron (BA.4/BA.5)– Neutralizing Titers at 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3)

End point title	SSD: Percentages of Participants With Seroresponse to the Omicron (BA.4/BA.5)– Neutralizing Titers at 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3) ^[66]
-----------------	---

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 4 for C4591048 Substudy D Group 2 and before Dose 3 for C4591007). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination assay result of $\geq 4 \times$ LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method. Percentage of participants achieving seroresponse at 1 month after study vaccination was reported in this endpoint. Evaluable immunogenicity population was analyzed. Results include those from a comparator group of C4591007 (NCT04816643) Phase 2/3 participants of the same age who received 3 doses of original BNT162b2 10 μ g as of the data cutoff date of 27 May 2022. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

1 month after Dose 4 for Group 2 and 1 month after Dose 3 for C4591007 control arm

Notes:

[66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD: Group 2: 3 prior doses of BNT162b2	SSD Historical cohort: C4591007 BNT162b2 10 mcg		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	101	112		
Units: Percentage of participants				
number (confidence interval 95%)	53.5 (43.3 to 63.5)	52.7 (43.0 to 62.2)		

Statistical analyses

Statistical analysis title	Group 2 and Historical cohort from C4591007
-----------------------------------	---

Statistical analysis description:

Adjusted difference in proportions based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category ($<$ median, $\geq$ median), expressed as a percentage (bivalent BNT162b2 [original/Omi BA.4/BA.5] 10 μ g - BNT162b2 10 μ g). 2-Sided CI, based on the Miettinen and Nurminen method for the difference in proportions stratified by baseline neutralizing titer category ($<$ median, $\geq$ median), expressed as a percentage.

Comparison groups	SSD: Group 2: 3 prior doses of BNT162b2 v SSD Historical cohort: C4591007 BNT162b2 10 mcg
Number of subjects included in analysis	213
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Percentage Difference
Point estimate	8.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.47
upper limit	19.99

Primary: SSD:Geometric Mean Ratio(GMR)Based on Geometric Mean Titers of Severe Acute Respiratory Syndrome Coronavirus 2(SARSCoV2)Omicron(BA.4/BA.5)-Neutralizing Titers at 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants(1 Month After Dose 3)

End point title	SSD:Geometric Mean Ratio(GMR)Based on Geometric Mean Titers of Severe Acute Respiratory Syndrome Coronavirus 2(SARSCoV2)Omicron(BA.4/BA.5)-Neutralizing Titers at 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants(1 Month After Dose 3) ^[67]
-----------------	--

End point description:

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the least square means and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status, and vaccine group as covariates. Evaluable immunogenicity population included all eligible randomised participants who received the study intervention to which they were randomised, had a valid and determinate immunogenicity result within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Results include those from a comparator group of C4591007 (NCT04816643) Phase 2/3 participants of the same age who received 3 doses of original BNT162b2 10 µg as of the data cutoff date of 27 May 2022. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

1 month after Dose 4 for Group 2 and 1 month after Dose 3 for C4591007 control arm

Notes:

[67] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD: Group 2: 3 prior doses of BNT162b2	SSD Historical cohort: C4591007 BNT162b2 10 mcg		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	101	112		
Units: Titers				
geometric mean (confidence interval 95%)	1836.1 (1593.8 to 2115.2)	1632.5 (1427.5 to 1867.0)		

Statistical analyses

Statistical analysis title	Group 2 and Historical cohort from C4591007
-----------------------------------	---

Statistical analysis description:

GMRs and 2-sided CIs were calculated by exponentiating the difference of LSMeans for the assay and the corresponding CIs based on a linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status, and vaccine group as covariates.

Comparison groups	SSD: Group 2: 3 prior doses of BNT162b2 v SSD Historical cohort: C4591007 BNT162b2 10 mcg
-------------------	---

Number of subjects included in analysis	213
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Geometric Mean Ratio
Point estimate	1.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.92
upper limit	1.37

Primary: SSE: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination

End point title	SSE: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination ^[68] ^[69]
-----------------	--

End point description:

Local reactions were recorded by participants or their parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (≥ 0.5 to 2.0 cm), moderate (> 2.0 to 7.0 cm), severe (> 7.0 cm) and Grade 4 (necrosis [redness and swelling] or exfoliative dermatitis [redness]). Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity, severe: prevented daily activity & Grade 4: ER visit/hospitalization. Grade 4 reactions were classified by investigator/medically qualified person. Safety population consisted of all participants who had received at least 1 dose of the study intervention. Here, "Number of Participants Analyzed (N)" signifies number of participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination

Notes:

[68] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[69] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSE; hence, only arms for SSE were included.

End point values	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg			
Subject group type	Reporting group			
Number of subjects analysed	302			
Units: Percentage of Participants				
number (confidence interval 95%)				
Redness: Any	6.0 (3.6 to 9.3)			
Redness: Mild	4.6 (2.6 to 7.7)			
Redness: Moderate	1.3 (0.4 to 3.4)			
Redness: Severe	0 (0.0 to 1.2)			
Redness: Grade 4	0 (0.0 to 1.2)			
Swelling: Any	9.3 (6.2 to 13.1)			
Swelling: Mild	6.0 (3.6 to 9.3)			

Swelling: Moderate	3.0 (1.4 to 5.6)			
Swelling: Severe	0.3 (0.0 to 1.8)			
Swelling: Grade 4	0 (0.0 to 1.2)			
Pain at the injection site: Any	42.7 (37.1 to 48.5)			
Pain at the injection site: Mild	31.5 (26.3 to 37.0)			
Pain at the injection site: Moderate	11.3 (7.9 to 15.4)			
Pain at the injection site: Severe	0 (0.0 to 1.2)			
Pain at the injection site: Grade 4	0 (0.0 to 1.2)			

Statistical analyses

No statistical analyses for this end point

Primary: SSE: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination

End point title	SSE: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination ^[70] ^[71]
-----------------	--

End point description:

Systemic events were recorded by participants or their parents/legal guardians in e-diary. Fever was defined as oral temperature ≥ 38.0 deg C and categorized as ≥ 38.0 -38.4 deg C, >38.4 -38.9 deg C, >38.9 -40.0 deg C & >40.0 deg C. Fatigue, headache, chills, new/worsened muscle pain & new/worsened joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity & severe: prevented daily routine activity. Vomiting was graded as mild: 1-2 times in 24h, moderate: >2 times in 24h, severe: required intravenous hydration. Diarrhea was graded as mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h & severe: 6 or more loose stools in 24h. For all systemic events except fever, G4=ER visit/hospitalization & were classified by investigator/medically qualified person. Safety population consisted of all participants who had received at least 1 dose of study intervention. "N"=participants evaluable and "n"=participants evaluable for each specified rows.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 up to Day 7 after study vaccination

Notes:

[70] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[71] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSE; hence, only arms for SSE were included.

End point values	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg			
Subject group type	Reporting group			
Number of subjects analysed	302			
Units: Percentage of Participants				
number (confidence interval 95%)				
Fever: Any (n=301)	4.7 (2.6 to 7.7)			
Fever: ≥ 38.0 to 38.4 deg C (n=301)	2.0 (0.7 to 4.3)			
Fever: >38.4 to 38.9 deg C (n=301)	1.7 (0.5 to 3.8)			

Fever: >38.9 to 40.0 deg C (n=301)	0.3 (0.0 to 1.8)			
Fever: >40.0 deg C (n=301)	0.3 (0.0 to 1.8)			
Fever: Unknown (n=301)	0.3 (0.0 to 1.8)			
Fatigue: Any (n=302)	14.9 (11.1 to 19.4)			
Fatigue: Mild (n=302)	7.6 (4.9 to 11.2)			
Fatigue: Moderate (n=302)	6.6 (4.1 to 10.0)			
Fatigue: Severe (n=302)	0.7 (0.1 to 2.4)			
Fatigue: Grade 4 (n=302)	0 (0.0 to 1.2)			
Headache: Any (n=302)	14.2 (10.5 to 18.7)			
Headache: Mild (n=302)	7.9 (5.2 to 11.6)			
Headache: Moderate (n=302)	6.0 (3.6 to 9.3)			
Headache: Severe (n=302)	0.3 (0.0 to 1.8)			
Headache: Grade 4 (n=302)	0 (0.0 to 1.2)			
Chills: Any (n=302)	5.6 (3.3 to 8.9)			
Chills: Mild (n=302)	3.6 (1.8 to 6.4)			
Chills: Moderate (n=302)	2.0 (0.7 to 4.3)			
Chills: Severe (n=302)	0 (0.0 to 1.2)			
Chills: Grade 4 (n=302)	0 (0.0 to 1.2)			
Vomiting: Any (n=302)	4.3 (2.3 to 7.2)			
Vomiting: Mild (n=302)	3.3 (1.6 to 6.0)			
Vomiting: Moderate (n=302)	1.0 (0.2 to 2.9)			
Vomiting: Severe (n=302)	0 (0.0 to 1.2)			
Vomiting: Grade 4 (n=302)	0 (0.0 to 1.2)			
Diarrhea: Any (n=302)	7.3 (4.6 to 10.8)			
Diarrhea: Mild (n=302)	6.0 (3.6 to 9.3)			
Diarrhea: Moderate (n=302)	1.3 (0.4 to 3.4)			
Diarrhea: Severe (n=302)	0 (0.0 to 1.2)			
Diarrhea: Grade 4 (n=302)	0 (0.0 to 1.2)			
New or worsened muscle pain: Any (n=302)	10.3 (7.1 to 14.3)			
New or worsened muscle pain: Mild (n=302)	4.6 (2.6 to 7.7)			
New or worsened muscle pain: Moderate (n=302)	5.6 (3.3 to 8.9)			
New or worsened muscle pain: Severe (n=302)	0 (0.0 to 1.2)			
New or worsened muscle pain: Grade 4 (n=302)	0 (0 to 1.2)			
New or worsened joint pain: Any (n=302)	4.6 (2.6 to 7.7)			
New or worsened joint pain: Mild (n=302)	2.0 (0.7 to 4.3)			
New or worsened joint pain: Moderate (n=302)	2.6 (1.2 to 5.2)			
New or worsened joint pain: Severe (n=302)	0 (0.0 to 1.2)			
New or worsened joint pain: Grade 4 (n=302)	0 (0.0 to 1.2)			

Statistical analyses

No statistical analyses for this end point

Primary: SSE: Percentage of Participants Reporting AEs 1 Month After Study Vaccination

End point title	SSE: Percentage of Participants Reporting AEs 1 Month After Study Vaccination ^{[72][73]}
-----------------	---

End point description:

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study vaccination, whether or not considered related to the study vaccination. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this endpoint. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this endpoint. Safety population consisted of all participants who had received at least 1 dose of the study intervention.

End point type	Primary
----------------	---------

End point timeframe:

Within 1 Month after study vaccination

Notes:

[72] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[73] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSE; hence, only arms for SSE were included.

End point values	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg			
Subject group type	Reporting group			
Number of subjects analysed	310			
Units: Percentage of Participants				
number (confidence interval 95%)	3.5 (1.8 to 6.3)			

Statistical analyses

No statistical analyses for this end point

Primary: SSE: Percentage of Participants Reporting SAEs Within 6 Months After Study Vaccination

End point title	SSE: Percentage of Participants Reporting SAEs Within 6 Months After Study Vaccination ^{[74][75]}
-----------------	--

End point description:

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-

threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Safety population consisted of all participants who have received at least 1 dose of the study intervention.

End point type	Primary
End point timeframe:	
Within 6 months after study vaccination	

Notes:

[74] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

[75] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSE; hence, only arms for SSE were included.

End point values	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg			
Subject group type	Reporting group			
Number of subjects analysed	310			
Units: Percentage of participants				
number (confidence interval 95%)	1.0 (0.2 to 2.8)			

Statistical analyses

No statistical analyses for this end point

Primary: SSE: GMR Based on GMT of SARS-CoV-2 Omicron XBB.1.5–Neutralizing Titers at 1 Month After Vaccination Compared With C4591054 – Substudy A Vaccine-Experienced Participants ≥ 12 Years of Age

End point title	SSE: GMR Based on GMT of SARS-CoV-2 Omicron XBB.1.5–Neutralizing Titers at 1 Month After Vaccination Compared With C4591054 – Substudy A Vaccine-Experienced Participants ≥ 12 Years of Age ^[76]
-----------------	--

End point description:

GMT is presented in descriptive section & GMR is presented in statistical analysis section. GMTs & corresponding 2-sided 95% CIs were calculated by exponentiating LS means & corresponding CIs based on analysis of log-transformed assay results using linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status & vaccine group as covariates. Evaluable immunogenicity population: All eligible participants who received study intervention to which they were assigned, had at least 1 valid and determinate immunogenicity results from the blood sample collected within 28 to 42 days after study vaccination, had no other important protocol deviations as determined by clinician. =participants evaluable for this endpoint.

End point type	Primary
End point timeframe:	
1 Month after vaccination	

Notes:

[76] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSE; hence, only arms for SSE were included.

End point values	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg	SSE Historical Cohort: C4591054 BNT162b2 (Omi XBB.1.5) 30mcg		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	285	300		
Units: Titer				
geometric mean (confidence interval 95%)	6569.3 (5781.6 to 7464.3)	3635.9 (3210.5 to 4117.6)		

Statistical analyses

Statistical analysis title	Geometric Mean Ratio
Statistical analysis description:	
GMRs and 2-sided CIs were calculated by exponentiating the difference of LS Mean for the assay and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status and vaccine group as covariates.	
Comparison groups	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg v SSE Historical Cohort: C4591054 BNT162b2 (Omi XBB.1.5) 30mcg
Number of subjects included in analysis	585
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[77]
Parameter estimate	Geometric Mean Ratio
Point estimate	1.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.51
upper limit	2.16

Notes:

[77] - Immunobridging success based on the GMR will be declared if the lower limit of the 2-sided 95% CI for the GMR is greater than 0.67 (1.5-fold criterion) and the point estimate of the GMR is ≥ 0.8 .

Primary: SSE: Percentage of Participants and Difference in Percentage of Participants With Seroresponse to Omicron XBB.1.5 at 1 Month After Study Vaccination Compared With C4591054 – Substudy A Vaccine-Experienced Participants ≥ 12 Years of Age

End point title	SSE: Percentage of Participants and Difference in Percentage of Participants With Seroresponse to Omicron XBB.1.5 at 1 Month After Study Vaccination Compared With C4591054 – Substudy A Vaccine-Experienced Participants ≥ 12 Years of Age ^[78]
-----------------	--

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (1 month after study vaccination for C4591048 SSE and 1 month after vaccination for C4591054). If the baseline measurement was below LLOQ, postvaccination assay result of $\geq 4 \times \text{LLOQ}$ was considered a seroresponse. Exact 2-sided 95% CI was based on Clopper and Pearson method. Percentage of participants with seroresponse were presented in descriptive analysis and difference in percentage of participants with seroresponse were presented in statistical analysis section. Evaluable immunogenicity population: All eligible participants with 1 dose of study vaccination to which they were assigned, had at least 1 valid & determinate immunogenicity result from blood sample collected within 28-42 days after study vaccination, had no other important protocol deviations as determined by clinician. 'N'=number of participants evaluable for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

1 Month after vaccination

Notes:

[78] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSE; hence, only arms for SSE were included.

End point values	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg	SSE Historical Cohort: C4591054 BNT162b2 (Omi XBB.1.5) 30mcg		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	285	300		
Units: Percentage of Participants				
number (confidence interval 95%)	88.8 (84.5 to 92.2)	77.0 (71.8 to 81.6)		

Statistical analyses

Statistical analysis title	Percentage of participants with seroresponse
Statistical analysis description:	
Adjusted difference in percentage based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category (<median, >=median), expressed as a percentage (C4591048 >=5 to <12 Years - C4591054 >=12 Years)).	
Comparison groups	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg v SSE Historical Cohort: C4591054 BNT162b2 (Omi XBB.1.5) 30mcg
Number of subjects included in analysis	585
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[79]
Parameter estimate	Difference in percentage
Point estimate	8.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.91
upper limit	14.02

Notes:

[79] - Immunobridging success based on seroresponse rate difference will be declared if the lower limit of the 2-sided 95% CI for the difference in percentages of participants with seroresponse is greater than -10%.

Secondary: SSB: GMR Based on Geometric Mean Titers of SARSCoV2 Reference-Strain-Neutralizing Titers at 1 Month After Dose 4 for Group 2 and at 1 Month After Dose 3 for C4591007 Phase 2/3 Participants

End point title	SSB: GMR Based on Geometric Mean Titers of SARSCoV2 Reference-Strain-Neutralizing Titers at 1 Month After Dose 4 for Group 2 and at 1 Month After Dose 3 for C4591007 Phase 2/3 Participants ^[80]
-----------------	--

End point description:

GMTs and the corresponding 2-sided CIs were calculated by exponentiating the least square means & the corresponding CIs based on analysis of log-transformed assay results using linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status & vaccine group as covariates. Assay results below the LLOQ were set to 0.5*LLOQ. Evaluable immunogenicity population

included all eligible participants who received the study intervention to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Results are presented for per-protocol subset which included a random sample of 240 participants selected from the full group and comprised the same percentages of participants in each age group & baseline SARS-CoV-2 infection status group as full group. 'N' = participants evaluable.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after Dose 4 for Group 2 and 1 month after Dose 3 for C4591007 control arm

Notes:

[80] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB Historical cohort: C4591007 BNT162b2 ≥ 6 months to < 2 years	SSB Historical cohort: C4591007 BNT162b2 3 mcg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	62	161	72	166
Units: Titers				
geometric mean (confidence interval 95%)	5965.4 (4958.5 to 7176.8)	6921.5 (6160.2 to 7777.0)	7108.9 (5989.2 to 8438.0)	7384.8 (6584.6 to 8282.3)

Statistical analyses

Statistical analysis title	Geometric Mean Ratio
----------------------------	----------------------

Statistical analysis description:

GMRs and 2-sided CIs were calculated by exponentiating the difference of LSMeans for the assay and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status, age group and vaccine group as covariates.

Comparison groups	SSB: Group 2b: 3 prior doses of BNT162b2 v SSB Historical cohort: C4591007 BNT162b2 3 mcg
Number of subjects included in analysis	327
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Geometric Mean Ratio
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	1.11

Statistical analysis title	Geometric Mean Ratio
----------------------------	----------------------

Statistical analysis description:

GMRs and 2-sided CIs were calculated by exponentiating the difference of LSMeans for the assay and

the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline log-transformed neutralizing titers, postbaseline infection status, age group and vaccine group as covariates.

Comparison groups	SSB: Group 2a: 3 prior doses of BNT162b2 v SSB Historical cohort:C4591007 BNT162b2 >=6 months to<2 years
Number of subjects included in analysis	134
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Geometric Mean Ratio
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	1.08

Secondary: SSB: Percentage of Participants With Seroresponse to the SARSCoV2 Reference-Strain-Neutralizing Titers at 1 Month After Dose 4 for Group 2 and at 1 Month After Dose 3 for C4591007 Phase 2/3 Participants

End point title	SSB: Percentage of Participants With Seroresponse to the SARSCoV2 Reference-Strain-Neutralizing Titers at 1 Month After Dose 4 for Group 2 and at 1 Month After Dose 3 for C4591007 Phase 2/3 Participants ^[81]
-----------------	--

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 4 for C4591048 Substudy B Group 2 and before Dose 3 for C4591007). If the baseline measurement was below LLOQ, the postvaccination assay result of $\geq 4 \times \text{LLOQ}$ was considered a seroresponse. Exact 2-sided 95% CI was based on Clopper and Pearson method. Evaluable immunogenicity population included all eligible participants who received the study intervention to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Results were presented for per-protocol subset which included a random sample of 240 participants selected from the full group and comprised of the same percentage of participants in each age group and baseline SARS-CoV-2 infection status group as the full group. 'N' = participants evaluable.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after Dose 4 for Group 2 and 1 month after Dose 3 for C4591007 control arm

Notes:

[81] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB Historical cohort: C4591007 BNT162b2 ≥ 6 months to < 2 years	SSB Historical cohort: C4591007 BNT162b2 3 mcg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	62	161	72	166
Units: Percentage of participants				
number (confidence interval 95%)	40.3 (28.1 to 53.6)	52.8 (44.8 to 60.7)	44.4 (32.7 to 56.6)	65.7 (57.9 to 72.8)

Statistical analyses

Statistical analysis title	Percentages of Participants With Seroresponse
Statistical analysis description: Adjusted difference in proportion based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category (<median, ≥median), expressed as a percentage (bivalent BNT162b2 [original/Omi BA.4/BA.5] 3 mcg - BNT162b2 3 mcg).	
Comparison groups	SSB: Group 2a: 3 prior doses of BNT162b2 v SSB Historical cohort:C4591007 BNT162b2 ≥6 months to<2 years
Number of subjects included in analysis	134
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[82]
Parameter estimate	Percentage Difference
Point estimate	5.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.43
upper limit	18.77

Notes:

[82] - Noninferiority was established if the lower bound of the 2-sided 95% CI for the difference in percentage was greater than -10%.

Secondary: SSB: GMT of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at Dose 4 and 1 Month After Dose 4

End point title	SSB: GMT of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at Dose 4 and 1 Month After Dose 4 ^[83]
End point description: GMT of SARS-CoV-2 Omicron strain–neutralizing titers at 1 month after the study vaccination was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 *LLOQ. Evaluable immunogenicity population included all eligible participants who received the study intervention to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis.'N'=participants evaluable for this endpoint.	
End point type	Secondary

End point timeframe:

Group 2: At Dose 4 and 1 month after Dose 4

Notes:

[83] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	78	196		
Units: Titers				
geometric mean (confidence interval 95%)				
At dose 4 (n=74, 192)	293.9 (195.4 to 441.9)	224.1 (177.2 to 283.5)		
1 month after Dose 4 (n=78, 196)	1905.1 (1328.9 to 2731.2)	2384.9 (1965.4 to 2893.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMT of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at Dose 3 and 1 Month After Dose 3: Group 1 Only

End point title	SSB: GMT of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at Dose 3 and 1 Month After Dose 3: Group 1 Only ^[84]
-----------------	---

End point description:

GMT of SARS-CoV-2 omicron BA.4/BA.5-neutralizing titers at dose 3 and 1 month after dose 3 was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 *LLOQ. Evaluable immunogenicity population (third dose) included all eligible participants who received first study intervention as third dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the third dose, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint. 'n'= Participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

At dose 3 and 1 month after dose 3

Notes:

[84] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	10		
Units: Titer				
geometric mean (confidence interval 95%)				
Dose 3 (n= 14, 10)	142.5 (45.6 to 444.9)	323.2 (83.7 to 1248.8)		
1 month after dose 3 (n=13, 10)	1548.9 (408.0 to 5879.6)	2699.9 (580.8 to 12551.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMT of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 4: Group 1 Only

End point title	SSB: GMT of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 4: Group 1 Only ^[85]
-----------------	--

End point description:

GMT of SARS-CoV-2 Omicron BA.4/BA.5–neutralizing titers at 1 month after dose 4 was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 *LLOQ. Evaluable immunogenicity population (fourth dose) included all eligible participants who received 2 doses of the study intervention as third and fourth dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

At 1 month after dose 4

Notes:

[85] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	9		
Units: Titer				
geometric mean (confidence interval 95%)	2800.0 (1260.5 to 6219.8)	4128.5 (1158.9 to 14708.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMT of SARS-CoV-2 Reference-Strain–Neutralizing Titers at Dose 4 and 1 Month After Dose 4

End point title	SSB: GMT of SARS-CoV-2 Reference-Strain–Neutralizing Titers at Dose 4 and 1 Month After Dose 4 ^[86]
-----------------	--

End point description:

GMT of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month after study

vaccination was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers & the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 * LLOQ. Evaluable immunogenicity population included all eligible participants who received the study intervention to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (at dose 4) and 1 Month after Dose 4

Notes:

[86] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	78	196		
Units: Titers				
geometric mean (confidence interval 99%)				
Pre-vaccination (n=74, 192)	1688.3 (1271.6 to 2241.6)	1734.9 (1466.0 to 2053.3)		
1 month after Dose 4 (n= 78,196)	6312.0 (5143.6 to 7746.0)	7897.3 (6952.0 to 8971.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMT of SARS-CoV-2 Reference-Strain–Neutralizing Titers at Dose 3 and 1 Month After Dose 3: Group 1 Only

End point title	SSB: GMT of SARS-CoV-2 Reference-Strain–Neutralizing Titers at Dose 3 and 1 Month After Dose 3: Group 1 Only ^[87]
-----------------	--

End point description:

GMT of SARS-CoV-2 reference strain–neutralizing titers at dose 3 and 1 month after dose 3 was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 * LLOQ. Evaluable immunogenicity population (third dose) included all eligible participants who received first study intervention as third dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the third dose, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint. 'n'= Participants evaluable for specified rows.

End point type	Secondary
----------------	-----------

End point timeframe:

At dose 3 and 1 month After dose 3

Notes:

[87] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	10		
Units: Titer				
geometric mean (confidence interval 95%)				
Dose 3 (n= 14, 10)	271.7 (114.6 to 644.3)	636.6 (262.7 to 1542.5)		
1 month after dose 3 (n= 13, 10)	3536.4 (2024.4 to 6177.6)	2576.5 (1204.5 to 5511.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After Dose 4: Group 1 Only

End point title	SSB: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After Dose 4: Group 1 Only ^[88]
-----------------	---

End point description:

GMT of SARS-CoV-2 reference strain-neutralizing titers at 1 month after dose 4 was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 *LLOQ. Evaluable immunogenicity population (fourth dose) included all eligible participants who received 2 doses of the study intervention as third and fourth dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

At 1 month after dose 4

Notes:

[88] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	9		
Units: Titer				
geometric mean (confidence interval	2357.1	2468.2		

95%)	(1485.0 to 3741.3)	(1188.8 to 5124.6)
------	--------------------	--------------------

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers From Dose 4 to 1 Month after Dose 4

End point title	SSB: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers From Dose 4 to 1 Month after Dose 4 ^[89]
-----------------	--

End point description:

GMFR of SARS-CoV-2 omicron BA.4/BA.5-neutralizing titers from dose 4 to 1 month after dose 4 was reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ in the analysis. Evaluable immunogenicity population included all eligible participants who received the study intervention to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

From dose 4 to 1 month after dose 4

Notes:

[89] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	74	192		
Units: Fold rise				
geometric mean (confidence interval 95%)	6.7 (5.1 to 8.8)	10.5 (8.9 to 12.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMFR of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers From Dose 3 to 1 Month After Dose 3: Group 1 Only

End point title	SSB: GMFR of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers From Dose 3 to 1 Month After Dose 3: Group 1 Only ^[90]
-----------------	---

End point description:

GMFR of SARS-CoV-2 omicron BA.4/BA.5-neutralizing titers from dose 3 to 1 month after dose 3 was

reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ in the analysis. Evaluable immunogenicity population (third dose) included all eligible participants who received first study intervention as third dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the third dose, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

From dose 3 to 1 month after dose 3

Notes:

[90] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	10		
Units: Fold rise				
geometric mean (confidence interval 95%)	9.1 (3.6 to 22.8)	8.4 (3.8 to 18.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMFR of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers From Dose 3 to 1 Month After Dose 4: Group 1 Only

End point title	SSB: GMFR of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers From Dose 3 to 1 Month After Dose 4: Group 1 Only ^[91]
-----------------	---

End point description:

GMFR of SARS-CoV-2 omicron BA.4/BA.5-neutralizing titers at dose 3 to 1 month After dose 4 was reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ in the analysis. Evaluable immunogenicity population (fourth dose) included all eligible participants who received 2 doses of the study intervention as third and fourth dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

From dose 3 to 1 month after dose 4

Notes:

[91] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	9		
Units: Fold rise				
geometric mean (confidence interval 95%)	14.9 (7.4 to 30.0)	17.2 (7.6 to 39.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMFR of SARS-CoV-2 Reference-Strain–Neutralizing Titers From Dose 4 to 1 Month after Dose 4

End point title	SSB: GMFR of SARS-CoV-2 Reference-Strain–Neutralizing Titers From Dose 4 to 1 Month after Dose 4 ^[92]
-----------------	--

End point description:

GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination from dose 4 to 1 month after dose 4 was reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 *LLOQ in the analysis. Evaluable immunogenicity population included all eligible participants who received the study intervention to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

From dose 4 to 1 month after dose 4

Notes:

[92] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	74	192		
Units: Fold rise				
geometric mean (confidence interval 95%)	3.7 (2.9 to 4.7)	4.5 (3.9 to 5.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMFR of SARS-CoV-2 Reference-Strain–Neutralizing Titers From

Dose 3 to 1 Month After Dose 3: Group 1 Only

End point title	SSB: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Dose 3 to 1 Month After Dose 3: Group 1 Only ^[93]
-----------------	--

End point description:

GMFR of SARS-CoV-2 reference strain-neutralizing titers from dose 3 to 1 month after dose 3 was reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ in the analysis. Evaluable immunogenicity population (third dose) included all eligible participants who received first study intervention as third dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the third dose, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

From dose 3 to 1 month after dose 3

Notes:

[93] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	10		
Units: Fold rise				
geometric mean (confidence interval 95%)	12.6 (4.9 to 32.1)	4.0 (2.2 to 7.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers At 1 Month After Dose 4: Group 1 Only

End point title	SSB: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers At 1 Month After Dose 4: Group 1 Only ^[94]
-----------------	--

End point description:

GMFR of SARS-CoV-2 reference strain-neutralizing titers at 1 month after dose 4 was reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ in the analysis. Evaluable immunogenicity population included all eligible participants who received 2 doses of the study intervention as third and fourth dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

At 1 month after dose 4

Notes:

[94] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	9		
Units: Fold rise				
geometric mean (confidence interval 95%)	8.8 (4.5 to 17.0)	4.6 (2.4 to 8.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: Percentage of Participants With Seroresponse to Reference-Strain-Neutralizing Titers at 1 Month After Dose 4

End point title	SSB: Percentage of Participants With Seroresponse to Reference-Strain-Neutralizing Titers at 1 Month After Dose 4 ^[95]
-----------------	---

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 4 for C4591048 Substudy B Group 2). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination assay result of $\geq 4 \times$ LLOQ was considered a seroresponse. Evaluable immunogenicity population included all eligible participants who received the study intervention to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Exact 2-sided 95% CI, based on the Clopper and Pearson method. Percentage of participants achieving seroresponse to reference-strain-neutralizing titers at 1 month after dose 4 was reported in this endpoint. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

1 Month after Dose 4

Notes:

[95] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	74	192		
Units: Percentage of participants				
number (confidence interval 95%)	43.2 (31.8 to 55.3)	52.1 (44.8 to 59.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: Percentage of Participants With Seroresponse to Reference-Strain-Neutralizing Titers at 1 Month After Dose 3: Group 1 Only

End point title	SSB: Percentage of Participants With Seroresponse to Reference-Strain-Neutralizing Titers at 1 Month After Dose 3: Group 1 Only ^[96]
-----------------	---

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 3). If the baseline measurement was below the LLOQ, the postvaccination assay result of $\geq 4 \times \text{LLOQ}$ was considered a seroresponse. Evaluable immunogenicity population (third dose) included all eligible participants who received first study intervention as third dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the third dose, and had no other important protocol deviations as determined by the clinician. Exact 2-sided 95% CI, based on the Clopper and Pearson method. Percentage of participants achieving seroresponse to reference-strain-neutralizing titers at 1 month after dose 3 was reported in this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after dose 3

Notes:

[96] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	10		
Units: Percentage of participants				
number (confidence interval 95%)	81.8 (48.2 to 97.7)	50.0 (18.7 to 81.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: Percentage of Participants With Seroresponse to Reference-Strain-Neutralizing Titers at 1 Month After Dose 4: Group 1 Only

End point title	SSB: Percentage of Participants With Seroresponse to Reference-Strain-Neutralizing Titers at 1 Month After Dose 4: Group 1 Only ^[97]
-----------------	---

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 3). If the baseline

measurement was below the LLOQ, the postvaccination assay result of $\geq 4 \times \text{LLOQ}$ was considered a seroresponse. Evaluable immunogenicity population (fourth dose) included all eligible participants who received 2 doses of the study intervention as third and fourth dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Exact 2-sided 95% CI, based on the Clopper and Pearson method. Percentage of participants achieving seroresponse to reference-strain-neutralizing titers at 1 month after dose 4 was reported in this endpoint. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

At 1 month after dose 4

Notes:

[97] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	9		
Units: Percentage of participants				
number (confidence interval 95%)	64.3 (35.1 to 87.2)	77.8 (40.0 to 97.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 4

End point title	SSB: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 4 ^[98]
-----------------	---

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 4 for C4591048 Substudy D Group 2). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination assay result of $\geq 4 \times \text{LLOQ}$ was considered a seroresponse. Evaluable immunogenicity population included all eligible participants who received the study intervention to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28-42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Exact 2-sided 95% CI, based on the Clopper and Pearson method. Percentage of participants achieving seroresponse to SARS-CoV-2 omicron BA.4/BA.5–neutralizing titers at 1 month after dose 4 was reported in this endpoint. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

1 Month after Dose 4

Notes:

[98] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	74	192		
Units: Percentage of participants				
number (confidence interval 95%)	56.8 (44.7 to 68.2)	74.5 (67.7 to 80.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 3: Group 1 Only

End point title	SSB: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 3: Group 1 Only ^[99]
-----------------	---

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 3). If the baseline measurement was below the LLOQ, the postvaccination assay result of $\geq 4 \times \text{LLOQ}$ was considered a seroresponse. Evaluable immunogenicity population (third dose) included all eligible participants who received first study intervention as third dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28–42 days after the third dose, and had no other important protocol deviations as determined by the clinician. Exact 2-sided 95% CI, based on the Clopper and Pearson method. Percentage of participants achieving seroresponse to SARS-CoV-2 omicron BA.4/BA.5–neutralizing titers at 1 month after dose 3 was reported in this endpoint. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after dose 3

Notes:

[99] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	10		
Units: Percentage of participants				
number (confidence interval 95%)	45.5 (16.7 to 76.6)	70.0 (34.8 to 93.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSB: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 4: Group 1 Only

End point title	SSB: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 4: Group 1 Only ^[100]
-----------------	--

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 3). If the baseline measurement was below the LLOQ, the postvaccination assay result of $\geq 4 \times \text{LLOQ}$ was considered a seroresponse. Evaluable immunogenicity population (fourth dose) included all eligible participants who received 2 doses of the study intervention as third and fourth dose to which they were assigned, had at least one valid and determinate immunogenicity result from the blood sample collected within 28–42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. Exact 2-sided 95% CI, based on the Clopper and Pearson method. Percentage of participants achieving seroresponse to SARS-CoV-2 omicron BA.4/BA.5–neutralizing titers at 1 month after dose 3 and 1 month after dose 4 was reported in this endpoint. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

At 1 month after dose 4

Notes:

[100] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSB; hence, only arms for SSB were included.

End point values	SSB: Group 1a: 2 prior doses of BNT162b2	SSB: Group 1b: 2 prior doses of BNT162b2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	9		
Units: Percentage of participants				
number (confidence interval 95%)	78.6 (49.2 to 95.3)	88.9 (51.8 to 99.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSD: Geometric Mean Titers (GMT) of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at Baseline and 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3)

End point title	SSD: Geometric Mean Titers (GMT) of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at Baseline and 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3) ^[101]
-----------------	---

End point description:

GMT of SARS-CoV-2 Omicron strain–neutralizing titers at 1 month after the study vaccination was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to $0.5 \times \text{LLOQ}$. Evaluable immunogenicity population was analyzed. Results include those from a comparator group of C4591007 (NCT04816643) Phase 2/3 participants of the same age who received 3 doses of original BNT162b2 10 µg as of the data cutoff date of 27 May 2022. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Group 2: Baseline and 1 month after Dose 4; C4591007 control arm: Baseline and 1 month after Dose 3

Notes:

[101] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD: Group 2: 3 prior doses of BNT162b2	SSD Historical cohort: C4591007 BNT162b2 10 mcg		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	102	113		
Units: Titers				
geometric mean (confidence interval 95%)				
Baseline (n=102,112)	488.3 (361.9 to 658.8)	248.3 (187.2 to 329.5)		
1 Month (n=102,113)	2189.9 (1742.8 to 2751.7)	1393.6 (1175.8 to 1651.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSD: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline and 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3)

End point title	SSD: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline and 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3) ^[102]
-----------------	--

End point description:

GMT of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month after study vaccination was reported in this endpoint. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers & the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ. Evaluable immunogenicity population was analyzed. Results include those from a comparator group of C4591007 (NCT04816643) Phase 2/3 participants of the same age who received 3 doses of original BNT162b2 10 µg as of the data cutoff date of 27 May 2022. Participants with or without evidence of prior infection were included in the analysis. 'N' = participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Group 2: Baseline and 1 month after Dose 4; C4591007 control arm: Baseline and 1 month after Dose 3

Notes:

[102] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD: Group 2: 3 prior doses of BNT162b2	SSD Historical cohort: C4591007 BNT162b2 10 mcg		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	102	113		
Units: Titers				
geometric mean (confidence interval 95%)				
Baseline	2904.0 (2372.6 to 3554.5)	1323.1 (1055.7 to 1658.2)		
1 Month	8245.9 (7108.9 to 9564.9)	7235.1 (6331.5 to 8267.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSD: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3)

End point title	SSD: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3) ^[103]
-----------------	--

End point description:

GMFR of SARS-CoV-2 omicron BA.4/BA.5-neutralizing titers at 1 month after study vaccination was reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis. Evaluable immunogenicity population was analyzed. Results include those from a comparator group of C4591007 (NCT04816643) Phase 2/3 participants of the same age who received 3 doses of original BNT162b2 10 µg as of the data cutoff date of 27 May 2022. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after Dose 4 for Group 2 and 1 month after Dose 3 for C4591007 control arm

Notes:

[103] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD: Group 2: 3 prior doses of BNT162b2	SSD Historical cohort: C4591007 BNT162b2 10 mcg		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	101	112		
Units: Fold rise				
geometric mean (confidence interval 95%)	4.5 (3.8 to 5.4)	5.6 (4.5 to 6.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSD: GMFR of SARS-CoV-2 Reference-Strain–Neutralizing Titers at 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3)

End point title	SSD: GMFR of SARS-CoV-2 Reference-Strain–Neutralizing Titers at 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3) ^[104]
End point description: GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month after study vaccination was reported in this endpoint. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis. Evaluable immunogenicity population was analyzed. Results include those from a comparator group of C4591007 (NCT04816643) Phase 2/3 participants of the same age who received 3 doses of original BNT162b2 10 µg as of the data cutoff date of 27 May 2022. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.	
End point type	Secondary
End point timeframe: 1 month after Dose 4 for Group 2 and 1 month after Dose 3 for C4591007 control arm	

Notes:

[104] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD: Group 2: 3 prior doses of BNT162b2	SSD Historical cohort: C4591007 BNT162b2 10 mcg		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	101	113		
Units: Fold rise				
geometric mean (confidence interval 95%)	2.8 (2.5 to 3.3)	5.5 (4.5 to 6.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSD: Percentages of Participants With Seroresponse to SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After Dose 4 for Group 2 and C4591007 Phase 2/3 Participants (1 Month After Dose 3)

End point title	SSD: Percentages of Participants With Seroresponse to SARS-CoV-2 Omicron BA.4/BA.5–Neutralizing Titers at 1 Month After
-----------------	---

End point description:

Seroresponse was defined as achieving ≥ 4 -fold rise from baseline (before Dose 4 for C4591048 Substudy D Group 2 and before Dose 3 for C4591007). If the baseline measurement was below the lower limit of quantification (LLOQ), the postvaccination assay result of $\geq 4 \times$ LLOQ was considered a seroresponse. Exact 2-sided 95% CI, based on the Clopper and Pearson method. Percentage of participants achieving seroresponse at 1 month after study vaccination was reported in this endpoint. Evaluable immunogenicity population was analyzed. Results include those from a comparator group of C4591007 (NCT04816643) Phase 2/3 participants of the same age who received 3 doses of original BNT162b2 10 µg as of the data cutoff date of 27 May 2022. Participants with or without evidence of prior infection were included in the analysis. 'N'=participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after Dose 4 for Group 2 and 1 month after Dose 3 for C4591007 control arm

Notes:

[105] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSD; hence, only arms for SSD were included.

End point values	SSD: Group 2: 3 prior doses of BNT162b2	SSD Historical cohort: C4591007 BNT162b2 10 mcg		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	101	112		
Units: Percentage of participants				
number (confidence interval 95%)	53.5 (43.3 to 63.5)	52.7 (43.0 to 62.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: SSE: GMT of SARS-CoV-2 Omicron XBB.1.5–Neutralizing Titers Before Vaccination and 1 Month After Vaccination

End point title	SSE: GMT of SARS-CoV-2 Omicron XBB.1.5–Neutralizing Titers Before Vaccination and 1 Month After Vaccination ^[106]
-----------------	--

End point description:

GMT of SARS-CoV-2 omicron XBB.1.5 neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5 *LLOQ. Evaluable immunogenicity population: All eligible participants who had received the study intervention to which they are assigned, had at least 1 valid and determinate immunogenicity results from the blood sample collected within 28 to 42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. 'N'=number of participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Before Vaccination and 1 Month after Study Vaccination

Notes:

[106] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSE; hence, only arms for SSE were included.

End point values	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg			
Subject group type	Reporting group			
Number of subjects analysed	285			
Units: Titer				
geometric mean (confidence interval 95%)				
Before Vaccination	195.0 (163.2 to 233.0)			
1 Month after Study Vaccination	5930.5 (5283.8 to 6656.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: SSE: GMFR of SARS-CoV-2 Omicron XBB.1.5–Neutralizing Titers From Before Study Vaccination to 1 Month After Vaccination

End point title	SSE: GMFR of SARS-CoV-2 Omicron XBB.1.5–Neutralizing Titers From Before Study Vaccination to 1 Month After Vaccination ^[107]
-----------------	---

End point description:

GMFR of SARS-CoV-2 omicron XBB.1.5 neutralizing titers from study vaccination to 1 month after study vaccination was reported in this outcome measure. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ in the analysis. Evaluable immunogenicity population: All eligible participants who had received the study intervention to which they are assigned, had at least 1 valid and determinate immunogenicity results from the blood sample collected within 28 to 42 days after the study vaccination, and had no other important protocol deviations as determined by the clinician. 'N'=number of participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

From before study vaccination to 1 month after study vaccination

Notes:

[107] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is specific to SSE; hence, only arms for SSE were included.

End point values	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg			
Subject group type	Reporting group			
Number of subjects analysed	285			
Units: Fold Rise				
number (confidence interval 95%)	30.4 (25.3 to 36.5)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Local reactions/systemic events(systematic assessment):upto Day(D)7 after vaccination.Non-SAEs(non-systematic assessment):From D1-1 month(M)after study vaccination.For All-cause mortality/SAE (non-systematic assessment) from D1-6M after study vaccination.

Adverse event reporting additional description:

Same event may appear as both non-SAE and SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and non-serious in another participants, or one participant may have experienced both serious and non-serious event during the study. MedDRA version used for sub-study E is 27.0

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

Reporting groups

Reporting group title	SSD: Group 1: 2 prior doses of BNT162b2
-----------------------	---

Reporting group description:

Participants aged 5 to 11 years who had received two prior doses of BNT162b2 10 microgram (mcg) 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSD: Group 2: 3 prior doses of BNT162b2
-----------------------	---

Reporting group description:

Participants aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg 90 to 240 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSD: Group 3: Participants from study C4591007 Phase 1
-----------------------	--

Reporting group description:

Participants from C4591007 phase 1 trial, aged 5 to 11 years who had received three prior doses of BNT162b2 10 mcg at least 90 days before enrollment in the study were included. Participants received a single dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 1a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 1b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 2a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 6 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSC: Group 2b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single (fourth) dose of BNT162b2 10 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 1a: 2 prior doses of BNT162b2 (First Vaccination)
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants

received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 3a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 1b: 2 prior doses of BNT162b2 (First Vaccination)
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 1a: 2 prior doses of BNT162b2 (Second Vaccination)
-----------------------	---

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 1b: 2 prior doses of BNT162b2 (Second Vaccination)
-----------------------	---

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 2a: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 6 months to < 2 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 2b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 10 mcg with the last dose received 60 to 240 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSB: Group 3b: 3 prior doses of BNT162b2
-----------------------	--

Reporting group description:

Participants from C4591007 (NCT04816643) phase 1 trial, aged ≥ 2 to < 5 years who had received three prior doses of BNT162b2 3 mcg with the last dose received at least 60 days before enrollment in the study were included. Participants received a single dose (fourth) of BNT162b2 3 mcg via intramuscular route on Day 1 of the study.

Reporting group title	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg
-----------------------	---

Reporting group description:

Participants aged 5 to 11 years who received a single dose of BNT162b2 (Omi XBB.1.5) 10 mcg via intramuscular route on Day 1 of this sub-study.

Serious adverse events	SSD: Group 1: 2 prior doses of BNT162b2	SSD: Group 2: 3 prior doses of BNT162b2	SSD: Group 3: Participants from study C4591007 Phase 1
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Injury, poisoning and procedural complications			
Post procedural haemorrhage			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Hypothermia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Faecaloma			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			

Breathing-related sleep disorder			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hyperglycaemia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Post procedural haemorrhage			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Hypothermia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Faecaloma			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breathing-related sleep disorder			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			

subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	SSC: Group 2b: 3 prior doses of BNT162b2	SSB: Group 1a: 2 prior doses of BNT162b2 (First Vaccination)	SSB: Group 3a: 3 prior doses of BNT162b2
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Post procedural haemorrhage			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

Hypothermia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Faecaloma			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breathing-related sleep disorder			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			

subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serious adverse events	SSB: Group 1b: 2 prior doses of BNT162b2 (First Vaccination)	SSB: Group 1a: 2 prior doses of BNT162b2 (Second Vaccination)	SSB: Group 1b: 2 prior doses of BNT162b2 (Second Vaccination)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
number of deaths (all causes)	0	0	0

number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Post procedural haemorrhage			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Hypothermia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Faecaloma			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric disorders			
Breathing-related sleep disorder			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB: Group 3b: 3 prior doses of BNT162b2
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 92 (0.00%)	1 / 218 (0.46%)	11 / 989 (1.11%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Post procedural haemorrhage			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	0 / 989 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Hypothermia			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Faecaloma			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	2 / 989 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breathing-related sleep disorder			
subjects affected / exposed	0 / 92 (0.00%)	1 / 218 (0.46%)	0 / 989 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Viral upper respiratory tract infection			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	0 / 989 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	1 / 989 (0.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 310 (0.97%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Post procedural haemorrhage			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Seizure			
subjects affected / exposed	1 / 310 (0.32%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			

Hypothermia			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Faecaloma			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchial hyperreactivity			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Breathing-related sleep disorder			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mental status changes			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cellulitis			

subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia viral			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	2 / 310 (0.65%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	SSD: Group 1: 2 prior doses of BNT162b2	SSD: Group 2: 3 prior doses of BNT162b2	SSD: Group 3: Participants from study C4591007 Phase 1
Total subjects affected by non-serious adverse events subjects affected / exposed	1 / 2 (50.00%)	88 / 113 (77.88%)	16 / 19 (84.21%)
Injury, poisoning and procedural complications			
Animal bite subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Arthropod bite subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Skin abrasion subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Contusion subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache (HEADACHE) alternative assessment type: Systematic subjects affected / exposed	0 / 2 (0.00%)	28 / 113 (24.78%)	7 / 19 (36.84%)
occurrences (all)	0	28	7
Somnolence (DROWSINESS) alternative assessment type: Systematic subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Somnolence subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Injection site haemorrhage subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	1 / 19 (5.26%)
occurrences (all)	0	0	1
Fatigue (FATIGUE) alternative assessment type: Systematic			

subjects affected / exposed	0 / 2 (0.00%)	45 / 113 (39.82%)	11 / 19 (57.89%)
occurrences (all)	0	45	11
Chills (CHILLS)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 2 (0.00%)	10 / 113 (8.85%)	2 / 19 (10.53%)
occurrences (all)	0	10	2
Injection site erythema (REDNESS)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 2 (0.00%)	8 / 113 (7.08%)	2 / 19 (10.53%)
occurrences (all)	0	8	2
Injection site swelling			
subjects affected / exposed	0 / 2 (0.00%)	5 / 113 (4.42%)	2 / 19 (10.53%)
occurrences (all)	0	5	2
Pyrexia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Injection site pain (PAIN)			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 2 (50.00%)	71 / 113 (62.83%)	13 / 19 (68.42%)
occurrences (all)	1	71	13
Pyrexia (FEVER)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 2 (0.00%)	5 / 113 (4.42%)	2 / 19 (10.53%)
occurrences (all)	0	5	2
Injection site erythema			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Injection site pain			

subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Injection site pain (TENDERNESS)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Injection site swelling (SWELLING)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Diarrhea (DIARRHEA)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 2 (0.00%)	4 / 113 (3.54%)	0 / 19 (0.00%)
occurrences (all)	0	4	0
Vomiting			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Vomiting (VOMITING)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 2 (0.00%)	4 / 113 (3.54%)	0 / 19 (0.00%)
occurrences (all)	0	4	0
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Tachypnoea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Skin and subcutaneous tissue disorders	Urticaria			
	subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
	Erythema			
	subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
Psychiatric disorders	Rash maculo-papular			
	subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
	Anxiety			
	subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	1 / 19 (5.26%)
	occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders	Irritability			
	subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
	Myalgia			
	alternative assessment type: Systematic			
	subjects affected / exposed	0 / 2 (0.00%)	15 / 113 (13.27%)	4 / 19 (21.05%)
Infections and infestations	occurrences (all)	0	15	4
	Arthralgia			
	alternative assessment type: Systematic			
	subjects affected / exposed	0 / 2 (0.00%)	10 / 113 (8.85%)	2 / 19 (10.53%)
	occurrences (all)	0	10	2
	Pain in extremity			
	subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0
	Upper respiratory tract infections			
	subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	1 / 19 (5.26%)
	occurrences (all)	0	0	1
	Conjunctivitis			
	subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
	occurrences (all)	0	0	0

Otitis media			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Impetigo			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Pharyngitis streptococcal			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 2 (0.00%)	0 / 113 (0.00%)	0 / 19 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	SSC: Group 1a: 3 prior doses of BNT162b2	SSC: Group 1b: 3 prior doses of BNT162b2	SSC: Group 2a: 3 prior doses of BNT162b2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 17 (76.47%)	17 / 19 (89.47%)	24 / 32 (75.00%)
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	0 / 17 (0.00%)	1 / 19 (5.26%)	0 / 32 (0.00%)
occurrences (all)	0	1	0
Skin abrasion			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0

Nervous system disorders Headache (HEADACHE) alternative assessment type: Systematic subjects affected / exposed occurrences (all) Somnolence (DROWSINESS) alternative assessment type: Systematic subjects affected / exposed occurrences (all) Somnolence subjects affected / exposed occurrences (all)	0 / 17 (0.00%)	0 / 19 (0.00%)	4 / 32 (12.50%)
	0	0	4
	5 / 17 (29.41%)	5 / 19 (26.32%)	0 / 32 (0.00%)
	5	5	0
	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
	0	0	0
General disorders and administration site conditions Injection site haemorrhage subjects affected / exposed occurrences (all) Fatigue (FATIGUE) alternative assessment type: Systematic subjects affected / exposed occurrences (all) Chills (CHILLS) alternative assessment type: Systematic subjects affected / exposed occurrences (all) Injection site erythema (REDNESS) alternative assessment type: Systematic subjects affected / exposed occurrences (all) Injection site swelling subjects affected / exposed occurrences (all) Pyrexia subjects affected / exposed occurrences (all) Fatigue	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
	0	0	0
	0 / 17 (0.00%)	0 / 19 (0.00%)	13 / 32 (40.63%)
	0	0	13
	0 / 17 (0.00%)	0 / 19 (0.00%)	4 / 32 (12.50%)
	0	0	4
	4 / 17 (23.53%)	4 / 19 (21.05%)	2 / 32 (6.25%)
	4	4	2
	0 / 17 (0.00%)	0 / 19 (0.00%)	2 / 32 (6.25%)
	0	0	2
	1 / 17 (5.88%)	0 / 19 (0.00%)	1 / 32 (3.13%)
	1	0	1

subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Injection site pain (PAIN)			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 17 (5.88%)	3 / 19 (15.79%)	10 / 32 (31.25%)
occurrences (all)	1	3	10
Pyrexia (FEVER)			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 17 (17.65%)	1 / 19 (5.26%)	8 / 32 (25.00%)
occurrences (all)	3	1	8
Injection site erythema			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Injection site pain (TENDERNESS)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Injection site swelling (SWELLING)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Diarrhea (DIARRHEA)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 17 (0.00%)	0 / 19 (0.00%)	2 / 32 (6.25%)
occurrences (all)	0	0	2

Vomiting subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 19 (5.26%) 1	0 / 32 (0.00%) 0
Vomiting (VOMITING) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 19 (0.00%) 0	3 / 32 (9.38%) 3
Respiratory, thoracic and mediastinal disorders Nasal congestion subjects affected / exposed occurrences (all) Cough subjects affected / exposed occurrences (all) Tachypnoea subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0 0 / 17 (0.00%) 0 0 / 17 (0.00%) 0	0 / 19 (0.00%) 0 0 / 19 (0.00%) 0 0 / 19 (0.00%) 0	0 / 32 (0.00%) 0 0 / 32 (0.00%) 0 0 / 32 (0.00%) 0
Skin and subcutaneous tissue disorders Urticaria subjects affected / exposed occurrences (all) Erythema subjects affected / exposed occurrences (all) Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0 0 / 17 (0.00%) 0 0 / 17 (0.00%) 0	0 / 19 (0.00%) 0 1 / 19 (5.26%) 1 0 / 19 (0.00%) 0	1 / 32 (3.13%) 1 0 / 32 (0.00%) 0 0 / 32 (0.00%) 0
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all) Irritability subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0 8 / 17 (47.06%) 8	0 / 19 (0.00%) 0 14 / 19 (73.68%) 14	0 / 32 (0.00%) 0 0 / 32 (0.00%) 0
Musculoskeletal and connective tissue disorders			

Myalgia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 19 (0.00%) 0	3 / 32 (9.38%) 3
Arthralgia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 19 (0.00%) 0	0 / 32 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 19 (0.00%) 0	0 / 32 (0.00%) 0
Infections and infestations			
Upper respiratory tract infections subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 19 (0.00%) 0	0 / 32 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 19 (0.00%) 0	0 / 32 (0.00%) 0
Otitis media subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 19 (0.00%) 0	0 / 32 (0.00%) 0
Gastroenteritis subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 19 (0.00%) 0	0 / 32 (0.00%) 0
Ear infection subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 19 (0.00%) 0	0 / 32 (0.00%) 0
Impetigo subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 19 (0.00%) 0	0 / 32 (0.00%) 0
Pharyngitis streptococcal subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 19 (0.00%) 0	0 / 32 (0.00%) 0
Metabolism and nutrition disorders Decreased appetite			

subjects affected / exposed	4 / 17 (23.53%)	3 / 19 (15.79%)	0 / 32 (0.00%)
occurrences (all)	4	3	0

Non-serious adverse events	SSC: Group 2b: 3 prior doses of BNT162b2	SSB: Group 1a: 2 prior doses of BNT162b2 (First Vaccination)	SSB: Group 3a: 3 prior doses of BNT162b2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 30 (56.67%)	14 / 17 (82.35%)	44 / 68 (64.71%)
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	1 / 68 (1.47%)
occurrences (all)	0	0	1
Nervous system disorders			
Headache (HEADACHE)			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 30 (3.33%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	1	0	0
Somnolence (DROWSINESS)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 30 (0.00%)	7 / 17 (41.18%)	11 / 68 (16.18%)
occurrences (all)	0	7	11
Somnolence			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Injection site haemorrhage			

subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	0	0	0
Fatigue (FATIGUE)			
alternative assessment type: Systematic			
subjects affected / exposed	11 / 30 (36.67%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	11	0	0
Chills (CHILLS)			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 30 (3.33%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	1	0	0
Injection site erythema (REDNESS)			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 30 (3.33%)	1 / 17 (5.88%)	4 / 68 (5.88%)
occurrences (all)	1	1	4
Injection site swelling			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	1 / 68 (1.47%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	0 / 30 (0.00%)	1 / 17 (5.88%)	2 / 68 (2.94%)
occurrences (all)	0	1	2
Fatigue			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	1 / 68 (1.47%)
occurrences (all)	0	0	1
Injection site pain (PAIN)			
alternative assessment type: Systematic			
subjects affected / exposed	8 / 30 (26.67%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	8	0	0
Pyrexia (FEVER)			
alternative assessment type: Systematic			
subjects affected / exposed	3 / 30 (10.00%)	0 / 17 (0.00%)	7 / 68 (10.29%)
occurrences (all)	3	0	7
Injection site erythema			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	1 / 68 (1.47%)
occurrences (all)	0	0	1
Chills			

subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	1 / 68 (1.47%)
occurrences (all)	0	0	1
Injection site pain			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	0	0	0
Injection site pain (TENDERNESS)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	8 / 68 (11.76%)
occurrences (all)	0	0	8
Injection site swelling (SWELLING)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	0	0	0
Diarrhea (DIARRHEA)			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 30 (3.33%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	3 / 68 (4.41%)
occurrences (all)	0	0	3
Vomiting (VOMITING)			
alternative assessment type: Systematic			
subjects affected / exposed	2 / 30 (6.67%)	0 / 17 (0.00%)	0 / 68 (0.00%)
occurrences (all)	2	0	0
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	1 / 68 (1.47%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	0 / 30 (0.00%)	0 / 17 (0.00%)	1 / 68 (1.47%)
occurrences (all)	0	0	1

Tachypnoea subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	1 / 68 (1.47%) 1
Skin and subcutaneous tissue disorders			
Urticaria subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	1 / 68 (1.47%) 1
Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	1 / 68 (1.47%) 1
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0
Irritability subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	11 / 17 (64.71%) 11	29 / 68 (42.65%) 29
Musculoskeletal and connective tissue disorders			
Myalgia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0
Arthralgia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0
Infections and infestations			
Upper respiratory tract infections subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0

Conjunctivitis subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0
Otitis media subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 17 (0.00%) 0	1 / 68 (1.47%) 1
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0
Ear infection subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0
Impetigo subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	0 / 68 (0.00%) 0
Pharyngitis streptococcal subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 17 (0.00%) 0	1 / 68 (1.47%) 1
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	4 / 17 (23.53%) 4	13 / 68 (19.12%) 13

Non-serious adverse events	SSB: Group 1b: 2 prior doses of BNT162b2 (First Vaccination)	SSB: Group 1a: 2 prior doses of BNT162b2 (Second Vaccination)	SSB: Group 1b: 2 prior doses of BNT162b2 (Second Vaccination)
Total subjects affected by non-serious adverse events subjects affected / exposed	7 / 13 (53.85%)	11 / 17 (64.71%)	5 / 13 (38.46%)
Injury, poisoning and procedural complications Animal bite subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 17 (0.00%) 0	0 / 13 (0.00%) 0
Arthropod bite subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 17 (0.00%) 0	0 / 13 (0.00%) 0
Skin abrasion			

subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 17 (0.00%) 0	0 / 13 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 17 (0.00%) 0	0 / 13 (0.00%) 0
Nervous system disorders Headache (HEADACHE) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 17 (0.00%) 0	0 / 13 (0.00%) 0
Somnolence (DROWSINESS) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 17 (11.76%) 2	0 / 13 (0.00%) 0
Somnolence subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 17 (5.88%) 1	0 / 13 (0.00%) 0
General disorders and administration site conditions Injection site haemorrhage subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 17 (0.00%) 0	0 / 13 (0.00%) 0
Fatigue (FATIGUE) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	4 / 13 (30.77%) 4	0 / 17 (0.00%) 0	3 / 13 (23.08%) 3
Chills (CHILLS) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 17 (0.00%) 0	0 / 13 (0.00%) 0
Injection site erythema (REDNESS) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	2 / 17 (11.76%) 2	0 / 13 (0.00%) 0
Injection site swelling			

subjects affected / exposed	1 / 13 (7.69%)	1 / 17 (5.88%)	0 / 13 (0.00%)
occurrences (all)	1	1	0
Pyrexia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Injection site pain (PAIN)			
alternative assessment type: Systematic			
subjects affected / exposed	4 / 13 (30.77%)	0 / 17 (0.00%)	1 / 13 (7.69%)
occurrences (all)	4	0	1
Pyrexia (FEVER)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 13 (0.00%)	2 / 17 (11.76%)	0 / 13 (0.00%)
occurrences (all)	0	2	0
Injection site erythema			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Injection site pain (TENDERNESS)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Injection site swelling (SWELLING)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Diarrhea (DIARRHEA)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Vomiting (VOMITING)			
alternative assessment type: Systematic			
subjects affected / exposed	1 / 13 (7.69%)	0 / 17 (0.00%)	1 / 13 (7.69%)
occurrences (all)	1	0	1
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Tachypnoea			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			

Anxiety			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	0 / 13 (0.00%)	9 / 17 (52.94%)	0 / 13 (0.00%)
occurrences (all)	0	9	0
Musculoskeletal and connective tissue disorders			
Myalgia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Arthralgia			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 13 (0.00%)	1 / 17 (5.88%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Upper respiratory tract infections			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 17 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Impetigo			

subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 17 (0.00%) 0	0 / 13 (0.00%) 0
Pharyngitis streptococcal subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 17 (0.00%) 0	0 / 13 (0.00%) 0
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	3 / 17 (17.65%) 3	0 / 13 (0.00%) 0

Non-serious adverse events	SSB: Group 2a: 3 prior doses of BNT162b2	SSB: Group 2b: 3 prior doses of BNT162b2	SSB: Group 3b: 3 prior doses of BNT162b2
Total subjects affected by non-serious adverse events subjects affected / exposed	48 / 92 (52.17%)	130 / 218 (59.63%)	532 / 989 (53.79%)
Injury, poisoning and procedural complications Animal bite subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Arthropod bite subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Skin abrasion subjects affected / exposed occurrences (all)	1 / 92 (1.09%) 1	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Nervous system disorders Headache (HEADACHE) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	9 / 218 (4.13%) 9	43 / 989 (4.35%) 43
Somnolence (DROWSINESS) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	18 / 92 (19.57%) 18	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Somnolence			

subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
General disorders and administration site conditions			
Injection site haemorrhage subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Fatigue (FATIGUE) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	68 / 218 (31.19%) 68	283 / 989 (28.61%) 283
Chills (CHILLS) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	10 / 218 (4.59%) 10	24 / 989 (2.43%) 24
Injection site erythema (REDNESS) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	7 / 92 (7.61%) 7	14 / 218 (6.42%) 14	100 / 989 (10.11%) 100
Injection site swelling subjects affected / exposed occurrences (all)	5 / 92 (5.43%) 5	9 / 218 (4.13%) 9	39 / 989 (3.94%) 39
Pyrexia subjects affected / exposed occurrences (all)	1 / 92 (1.09%) 2	3 / 218 (1.38%) 3	8 / 989 (0.81%) 8
Fatigue subjects affected / exposed occurrences (all)	1 / 92 (1.09%) 1	0 / 218 (0.00%) 0	2 / 989 (0.20%) 2
Injection site pain (PAIN) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Pyrexia (FEVER) alternative assessment type: Systematic			

subjects affected / exposed	8 / 92 (8.70%)	15 / 218 (6.88%)	51 / 989 (5.16%)
occurrences (all)	8	15	51
Injection site erythema			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	0 / 989 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	0 / 989 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	1 / 92 (1.09%)	1 / 218 (0.46%)	0 / 989 (0.00%)
occurrences (all)	1	1	0
Injection site pain (TENDERNESS)			
alternative assessment type: Systematic			
subjects affected / exposed	10 / 92 (10.87%)	0 / 218 (0.00%)	0 / 989 (0.00%)
occurrences (all)	10	0	0
Injection site swelling (SWELLING)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 92 (0.00%)	0 / 218 (0.00%)	0 / 989 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	2 / 92 (2.17%)	0 / 218 (0.00%)	0 / 989 (0.00%)
occurrences (all)	2	0	0
Diarrhea (DIARRHEA)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 92 (0.00%)	11 / 218 (5.05%)	68 / 989 (6.88%)
occurrences (all)	0	11	68
Vomiting			
subjects affected / exposed	2 / 92 (2.17%)	1 / 218 (0.46%)	7 / 989 (0.71%)
occurrences (all)	2	1	7
Vomiting (VOMITING)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 92 (0.00%)	11 / 218 (5.05%)	47 / 989 (4.75%)
occurrences (all)	0	11	47
Respiratory, thoracic and mediastinal disorders			

Nasal congestion subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	1 / 989 (0.10%) 1
Cough subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	2 / 989 (0.20%) 2
Tachypnoea subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Skin and subcutaneous tissue disorders			
Urticaria subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	1 / 92 (1.09%) 1	1 / 218 (0.46%) 1	0 / 989 (0.00%) 0
Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Irritability subjects affected / exposed occurrences (all)	32 / 92 (34.78%) 32	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Myalgia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	7 / 218 (3.21%) 7	20 / 989 (2.02%) 20
Arthralgia alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Pain in extremity			

subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Infections and infestations			
Upper respiratory tract infections subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	1 / 92 (1.09%) 1	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Otitis media subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	3 / 989 (0.30%) 3
Gastroenteritis subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Ear infection subjects affected / exposed occurrences (all)	1 / 92 (1.09%) 1	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Impetigo subjects affected / exposed occurrences (all)	1 / 92 (1.09%) 1	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0
Pharyngitis streptococcal subjects affected / exposed occurrences (all)	0 / 92 (0.00%) 0	0 / 218 (0.00%) 0	2 / 989 (0.20%) 2
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	18 / 92 (19.57%) 18	0 / 218 (0.00%) 0	0 / 989 (0.00%) 0

Non-serious adverse events	SSE: Monovalent BNT162b2 (Omi XBB.1.5) 10 mcg		
Total subjects affected by non-serious adverse events subjects affected / exposed	164 / 310 (52.90%)		
Injury, poisoning and procedural complications			
Animal bite subjects affected / exposed occurrences (all)	0 / 310 (0.00%) 0		

Arthropod bite subjects affected / exposed occurrences (all)	0 / 310 (0.00%) 0		
Skin abrasion subjects affected / exposed occurrences (all)	0 / 310 (0.00%) 0		
Contusion subjects affected / exposed occurrences (all)	0 / 310 (0.00%) 0		
Nervous system disorders Headache (HEADACHE) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	43 / 310 (13.87%) 43		
Somnolence (DROWSINESS) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	0 / 310 (0.00%) 0		
Somnolence subjects affected / exposed occurrences (all)	0 / 310 (0.00%) 0		
General disorders and administration site conditions Injection site haemorrhage subjects affected / exposed occurrences (all)	0 / 310 (0.00%) 0		
Fatigue (FATIGUE) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	45 / 310 (14.52%) 45		
Chills (CHILLS) alternative assessment type: Systematic subjects affected / exposed occurrences (all)	17 / 310 (5.48%) 17		
Injection site erythema (REDNESS) alternative assessment type: Systematic			

subjects affected / exposed	18 / 310 (5.81%)		
occurrences (all)	18		
Injection site swelling			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Injection site pain (PAIN)			
alternative assessment type: Systematic			
subjects affected / exposed	129 / 310 (41.61%)		
occurrences (all)	129		
Pyrexia (FEVER)			
alternative assessment type: Systematic			
subjects affected / exposed	14 / 310 (4.52%)		
occurrences (all)	14		
Injection site erythema			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Chills			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Injection site pain			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Injection site pain (TENDERNESS)			
alternative assessment type: Systematic			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Injection site swelling (SWELLING)			
alternative assessment type: Systematic			

subjects affected / exposed occurrences (all)	28 / 310 (9.03%) 28		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Diarrhea (DIARRHEA)			
alternative assessment type: Systematic			
subjects affected / exposed	22 / 310 (7.10%)		
occurrences (all)	22		
Vomiting			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Vomiting (VOMITING)			
alternative assessment type: Systematic			
subjects affected / exposed	13 / 310 (4.19%)		
occurrences (all)	13		
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Tachypnoea			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			

subjects affected / exposed occurrences (all)	0 / 310 (0.00%) 0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Irritability			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Myalgia			
alternative assessment type: Systematic			
subjects affected / exposed	31 / 310 (10.00%)		
occurrences (all)	31		
Arthralgia			
alternative assessment type: Systematic			
subjects affected / exposed	14 / 310 (4.52%)		
occurrences (all)	14		
Pain in extremity			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Upper respiratory tract infections			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Otitis media			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Ear infection			

subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Impetigo			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Pharyngitis streptococcal			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 310 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 October 2022	Amendment 1: SSB: Updated section 1.1 Increased samples size in Group 2 to 300 and Group 3 to 3600; Decreased the number of days since last dose prior to enrollment in Group 3 to 60 days;Removed restriction on Group 3 that only participants from the C4591007 study in Phase 1 could participate; Updated section 10.8.3: Updated and added objectives, estimands, and endpoints to demonstrate noninferiority with respect to the level of neutralizing titers and the seroresponse rate of the anti-reference-strain immune response;Updated Section 10.8.9.1.2: Added multiplicity adjustment method for evaluating superiority and noninferiority with respect to level of neutralizing titer for GMR and seroresponse rate; Updated Section 10.8.9.3.2:Clarified immunogenicity endpoint analysis and success criterion for newly added superiority and noninferiority of anti-Omicron BA.4/BA.5 immune response objective;Updated Section 10.8.9.5 Added sample size and power calculation for the newly added superiority and noninferiority of anti- Omicron and anti-reference-strain immune response objectives SSD: Updated section 1.1 :Decreased the number of days since last dose prior to enrollment in Group 3 to 90 days. Updated Sections 10.7.5.2, 10.8.5.2, 10.9.5.2, 10.10.5.2 Exclusion Criteria Substudy A, B, C, D: Added radiotherapy,within 60 days before enrollment. Updated section 10.10.3 Clarified that the primary immunogenicity comparison would be between the SSD Group 1 to C4591007 Phase 2/3 participants and made editorial change to the estimands. Updated section 10.10.1.2: Removed 1-month postdose blood draw group 3 only. Updated section 10.10.1.3.2: Added the group numbers to rows specific to blood sample collection. Updated section 10.10.1.3.2: Added row specific to Group 3 blood draw to be collected at baseline only.
18 November 2022	Amendment 2: Updated high-level overview table to reflect Substudy C updates Section 1.1 Synopsis; Updated Substudy C study design text to reflect defined age groups and update to sample size in Section 1.1 Synopsis, Section 10.9.1.2 Schema, Section 10.9.4.1 Overall Design, Section 10.9.6.4 Blinding; Clarified AE reporting guidance for potential COVID-19/MIS-C illnesses and their sequelae to be consistent with Section 8.4.7
01 August 2023	Amendment 3: SSB: Updated Section 10.8.3: Added a secondary immunogenicity endpoint for SARS-CoV-2 reference-strain- neutralizing titers(previously omitted) SSC: Updated Section 10.9 Removed all references to the Phase 2/3 portion of Substudy C;Updated Section 10.9.1 Updated expanded enrollment numbers in Substudy C Phase 1 to reflect actual enrollment figures SSD: Updated section: 10.10.3: Added "at 1 month after Dose 4" to the second primary immunogenicity objective.
01 September 2023	Amendment 4:SSB: Updated Section 10.8.3 and Section 10.8.9.3.2 Removed objectives for immunogenicity comparisons related to Group 1. Section 10.8.9.2 Corrected the description of the all-available immunogenicity population to reflect all assigned participants instead of all randomized participants.SSC: Updated Section 10.9.3 and Section 10.9.9.3. Removed the analysis across both age groups combined. 2SSD: Updated section 10.10.3 and 10.10.9.3.2: Removed objectives for immunogenicity comparisons and descriptive summaries related to Group 1. Added a new Substudy E to evaluate a single dose of BNT162b2 (Omi XBB.1.5) in COVID-19 vaccine-naïve individuals ≥ 2 to 12 years of age.

05 July 2024	Amendment 5: Updated Substudy E primary and secondary objectives, statistical hypotheses, and the primary, secondary, and tertiary endpoints, estimands, and analyses Updated Section 10.11.3 Objectives, Estimands, and Endpoints, Section 10.11.9.1 Statistical Hypotheses, and Section 10.11.9.3 Statistical Analyses. updated inclusion and exclusion criteria for Substudy E; Updated Section 10.7.5.2 Exclusion Criteria, Section 10.11.5.1 Inclusion Criteria, and Section 10.11.5.2 Exclusion Criteria; Updated the timing of the statistical analyses for Substudy E Section 10.11.9.4.1 Analysis Timing Updated Substudy E immunogenicity assessments Updated Section 10.11.9.5 Sample Size Determination
--------------	---

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported